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Abstract
Mutations of the autoimmune regulator gene (AIRE) lead to the development of the
multiple organ specific autoimmune disease, autoimmune polyendocrine syndrome
type 1 (APS1). Aire is known to have a role in central tolerance through regulating
the expression of self-antigens in the thymus. Prevention of autoimmune disease also
relies on peripheral control of any autoreactive T cells which do exit the thymus,
however, the role of Aire in the maintenance of these mechanisms, if any, is
unknown.
Thus, the hypothesis of this thesis was that lack of functional Aire affects peripheral
T cell function and that Aire plays a role in peripheral tolerance.
Initially, the disease phenotype and genotype of APS1 patients in the UK was
determined. The phenotype of the peripheral lymphocytes of a small number of these
patients was determined through assessment of cell surface markers by flow
cytometry. The ability of these cells to proliferate when stimulated through the T cell
receptor was then assessed, this revealed a trend to a higher maximal proliferative
response in patients compared to controls. Cytokine production in response to T cell
stimulation showed a trend to a decrease in IFN-y and TNF-a in patients compared
to controls.
The tissue and cellular distribution of Aire in mice was characterised and Aire was
found to be expressed in tissues of the immune system along with a number of other
tissues, where its expression was predominantly limited to epithelial cells. Given the
cellular distribution of Aire, i.e. within speckles in the nucleus, its interaction with
nuclear proteins investigated. Aire was found to interact with paraspeckle protein 1.
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The role of Aire in CD4+ T cells was then investigated. Aire was found to be up-
regulated upon activation through the T cell receptor, at the mRNA and protein level.
This up-regulation of Aire could be abrogated by inhibiting signalling through
Notch, a developmental gene pathway which may play a role in peripheral tolerance.
Thus, it is possible that Aire may be regulated by a component of the Notch





At the time this thesis was commenced, the autoimmune regulator gene (AIRE), had
recently been cloned (2,3). AIRE was so named, as mutations in this gene cause
autoimmune polyendocrine syndrome type 1 (APS1) (OMIM 240300), a rare
autosomal recessive disorder characterised by multiple autoimmune diseases (4).
These first descriptions of AIRE revealed that it is expressed highly within the
thymus (2,3). Further descriptions showed that within the thymus, the expression of
AIRE is predominantly within the medullary epithelial cells (5,6,7,8). The medullary
epithelial cells (MEC) are known to mediate negative selection of T lymphocytes (9),
and MEC express tissue specific antigens such that antigens encountered in the
periphery are present within the thymus (10,11,12). This promiscuous expression of
peripheral antigens and negative selection of T cell clones specific to these antigens
is in part under the control of aire (13). Therefore, aire may play a role in central
tolerance through the expression of peripheral antigens and negative selection of
thymocytes specific for these antigens. However, it is probable that some
autoreactive T cell clones will escape this process of negative selection and will be
subjected to mechanisms of peripheral tolerance to prevent the development of
autoimmune disease. Whether aire plays a role in peripheral T cells and their
responses is the subject of this thesis.
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1.1 Autoimmune poiyendocrinopathy syndrome type 1
(APS1)
The autoimmune poiyendocrinopathy syndrome type 1 (APS1) is characterised by
autoimmune hypoparathyroidism, autoimmune adrenal failure and chronic
mucocutaneous candidiasis. The AIRE gene was originally identified because it is
mutations in this gene that cause APS1 (2,14,15,3,1,16,17,18), a rare autosomal
recessive form of human endocrine autoimmunity (4). The familial syndrome known
as APS1 was first described by Whitaker in 1956 (19), however the first description
of hypoparathyroidism associated with candidiasis was in 1929 (20), with the
association with hypoadrenalism being reported in 1946 (21). APS1 is also known as
Whitaker's syndrome, polyglandular autoimmune disease type 1 or autoimmune
poiyendocrinopathy, candidiasis and ectodermal dystrophy (APECED).
1.1.1 Prevalence
APS1 is rare with the highest prevalence seen in Finnish and Iranian Jewish
populations due to founder effects with a prevalence of approximately 1 in 25000
and 1 in 9000 respectively. In the UK it is estimated to affect approximately 3 per
million of the population.
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1.1.2 Genetics of APS1
Numerous mutations have been described in the AIRE gene (Fig 1.1). In order to
make the description of these more meaningful, I shall briefly describe the structure
of the AIRE gene.
The human autoimmune regulator gene (AIRE) is encoded on chromosome 21q22.3
(22), and, as described above, was cloned in 1997 by two independent groups (2,3).
It has 14 exons that encode a 2445 base pair transcript. The translated protein has
545 amino acids and a molecular weight of 57.5 kDa (3). The murine Aire gene
shows a high degree of homology to the human gene (23,5,24).
When cloned, AIRE was identified to have many features suggestive of a role as a
transcription factor (Fig 1.1). These conserved domains include a nuclear
localisation signal, a proline rich region, two plant homeodomain (PHD)-type zinc
fingers, four nuclear receptor interaction (LAXLL) motifs, an inverted LXXLL motif
and a variant of this (LXXLL) (2,3). Clearly the nuclear localisation signal suggests
that this is a nuclear protein, and this in combination with the LXXLL motifs and the
PHD fingers, which are found in nuclear proteins including transcriptional
coactivators, hint at a role in the regulation of gene expression (25). AIRE also
contains a SAND domain (SplOO, AIRE-1, NucP41/75, DEAF-1); this domain is
thought to function as a DNA binding domain and this feature in conjunction with
the PHD fingers led Gibson et al to propose that AIRE regulates gene expression by
modulating chromatin structure (25). More recently, the DNA binding ability of the
SAND domain was confirmed (26). Kumar et al demonstrated that AIRE
homodimers and tetramers can bind DNA (27), although this DNA binding may not
be mediated by the SAND domain, as the KDWK motif, which mediates DNA
25
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The commonest mutation in the UK APS1 population is a 13 base pair deletion in
exon 8 which gives rise to a protein truncated at the start of the first zinc finger motif
(1), whilst in the Finnish APS1 population, the major mutation is a nonsense
mutation in exon 6 encoding a protein truncated in the SAND domain and containing
neither zinc finger (2,3). In addition to these major mutations, there are many other
mutations often arising de novo in individual families. APS1 is an autosomal
recessive disease, thus patients are either homozygotes for the mutation, or more
commonly in the case of new mutations, compound heterozygotes. However, despite
the wide variety of mutations seen, no genotype-phenotype correlation has been
reported, rather it appears that the spectrum of disease present reflects the
combination of genetic susceptibility factors and environmental influences acting in
individual patients.
As APS1 is characterised by the development of multiple autoimmune diseases, the
possibility of an HLA association has been investigated. Unsurprisingly, there is no
association between with APS1 and HLA type, as APS1 is caused by mutations in
the AIRE gene. However, there may be an association between the development of
certain disease manifestations and HLA type. HLA-A3 occurs more frequently in
patients with ovarian failure (29), whilst none of 11 APS1 patients with type 1
diabetes, but 15 of 56 APS1 patients without type 1 diabetes had the DQB*0602
allele, which is protective for diabetes (30).
1.1.3 Clinical Features
APS1 usually manifests in early childhood and is characterised by
hypoparathyroidism, hypoadrenalism and chronic mucocutaneous candidiasis
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(CMC). Clinical diagnosis is based on the presence of two of these three cardinal
features (4).
The first manifestation to occur is usually CMC, generally by 5 years of age,
although it can occur as early as the first few months after birth (4,31,32). CMC is
seen in 73-100% of patients (4,32), although it occurs less frequently in Iranian Jews
and when present is less severe (33). CMC affects the oral, vaginal and oesophageal
membranes, nails and dermis (4).
Hypoparathyroidism tends to occur next, being present in 76-93% of patients, usually
by 10 years of age but can occur as early as 3 months of age and has been reported to
occur as late as 44 years of age (4,32,34). Autoantibodies to the extracellular domain
of the calcium-sensing receptor have been found in over half of patients with
acquired hypoparathyroidism, the majority of whom had APS1 (35).
The third of the cardinal features of APS1, Addison's disease, is usually present by
15 years of age, but has been reported to occur from 36 months to 41 years (4,32).
This manifestation occurs in 72-100% of patients with APS1 (4,32,34). Adrenal
cortex autoantibodies and steroid-producing cell autoantibodies have been
demonstrated in patients with APS1 with Addison' disease (32). The autoantigens
recognised by these autoantibodies are P450 17a-hydroxylase (P450 17a-OH), P450
side-chain cleavage (P450scc) and P450 21-hydroxylase (P450 21-OH)
(36,37,38,39).
In addition to these manifestations, a variety of other autoimmune diseases occur in
APS1. In a major Finnish series of 68 patients, 43% of patients had 4 or more disease
manifestations (4). Autoimmune gonadal failure occurs in approximately 17-50% of
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patients, these have steroid-producing cell autoantibodies (4,32,34). Malabsorption,
occurs in 15-22% of patients (4,32,34), its course often fluctuates, and this has a
major impact on all the other manifestations due to effects on the absorption of food
and medication. In some patients this is due to coeliac disease (40), however, in
many there is no obvious cause. The malabsorption does however appear to be
autoimmune in nature, and 48% of APS1 patients were found to have autoantibodies
to tryptophan hydroxylase, whilst no patients with other autoimmune diseases or
healthy controls were positive for these antibodies (41). In addition, serum from
these antibody-positive APS1 patients specifically stained tryptophan-hydroxylase-
containing enterochromaffin cells in normal duodenal mucosa and there was an
absence of serotonin-containing cells in duodenal biopsy samples from APS1
patients (41). Cholelithiasis occurs in APS1 patients at an earlier age than the general
population. This is thought to be secondary to malabsorption, leading to low levels of
bile acid in the gallbladder through disruption of the bile acid cycle (42).
Type 1 diabetes (T1D) occurs in 12 to 18% of APS1 patients (4,43). The majority of
these patients have islet cell and/or glutamic acid decarboxlyase (GAD) antibodies
(43).
Numerous other autoimmune manifestations have been reported. These include
thyroid disease, pernicious anaemia, hepatitis, vitiligo and alopecia (4). Autoimmune
asplenism may also be present, as a progressive process, leading to characteristic
findings on a blood smear, i.e. Howell-Jolly bodies, target cells, burr cells and
thrombocytosis (42).
Ectodermal dystrophy also occurs, affecting the nails and teeth, with defective dental
enamel formation. At one time this was thought to be a consequence of
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hypoparathyroidism, however as it is not seen following surgical hypoparathyroidism
and can occur after the correction of the low calcium, this is no longer thought to be
the case (32).
1.1.4 Prediction of disease manifestations
A notable feature of the APS1 series reported is the fact that there are unexplained
deaths both in patients and their siblings (4.44,45). These are usually attributed to
undiagnosed Addison's disease, hypoparathyroidism or fulminant sepsis (possibly
secondary to undiagnosed hyposplenism) (45). In view of this, the ability to predict
new manifestations to enable targeted screening would be advantageous.
As is the case with most complex autoimmune diseases, in APS1 autoantibodies
occur more frequently than the disease for which they are a marker. In APS1
autoantibodies against glutamic acid decarboxylase (GAD) are present more
commonly than T1D, being found in 32% of patients (46), making the positive
predictive value of GAD65 antibodies for T1D in APS1 approximately 27% (43).
Recently it has been suggested that antibodies against the IA-2 tyrosine phosphatase-
like protein (IA-2 ab) or insulin (IAA) are better markers of active beta cell loss, with
a positive predictive value in APS1 patients of 67% for T1D (30). But it is clear that
measurement of autoantibodies alone is not sufficient to predict diabetes
development in APS1 patients, therefore at present, the only tool available to the
clinician is regular screening (45).
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1.1.5 Aire mutations and complex autoimmune diseases
Given the broad spectrum of organ specific autoimmune diseases seen in APS1, it is
unsurprising that various researchers have investigated the role of AIRE mutations in
complex autoimmune diseases, in particular Addison's disease, autoimmune thyroid
disease and diabetes. Three independent groups have found no evidence for
heterozygous mutations in AIRE having a role in the development of these
autoimmune diseases (47,48,49).
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1.2 The autoimmune regulator gene
The structure of AIRE is described in section 1.1.2. Briefly it has features suggestive
of a role as a transcription factor including a nuclear localisation signal and several
domains capable of mediating protein-protein and protein-DNA interactions.
1.2.1 Subcellular localisation of AIRE
Full length AIRE protein is targeted to the nucleus as predicted by the nuclear
localisation signal (50,51,52). Within the nucleus, AIRE is expressed in a
characteristic speckled pattern which has been likened to nuclear bodies
(50,51,52,8,53). However, AIRE does not colocalise with SplOO or PML, proteins
which are components of nuclear bodies (51,52). In transfected cell lines a fibrillar
pattern of cytoplasmic staining is also seen (50,51,52) that is similar in distribution to
microtubules and was demonstrated to colocalise with a tubulin and vimentin, which
associate with microtubules (52).
The nuclear localisation of AIRE in the presence of a consensus nuclear localisation
signal (NLS) is strongly suggestive that this NLS is functional. Proof of this was
provided by a construct consisting of the AIRE NLS and green fluorescent protein
(GFP). This construct was transiently expressed in COS-1 cells and the GFP was
seen to localise to the nucleus (50). In addition to this N terminal NLS, construction
of N-terminal deletion AIRE constructs revealed an additional C terminal nuclear
transport signal that is functional irrespective of the N terminal NLS (50).
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The localisation to microtubular structures is mediated via the N terminal
homogenously staining region (HSR), a region which is also required for
homodimerisation (50,54).
As might be expected for a protein that is expressed both in the nucleus and
cytoplasm, the AIRE protein contains putative nuclear export sequences (28).
Although the AIRE nuclear export sequences are not identical to the consensus for
the CRM-1-mediated nuclear export system, leptomycin B (LMB), which is a
specific inhibitor of the CRM-1-mediated nuclear export pathway, leads to an
increase in nuclear localisation of AIRE at the expense of cytoplasmic localisation
(50).
1.2.2 Transcriptional activator function of AIRE
The nuclear location and presence of domains associated with other transcription
factors such as the proline rich region (PRR) and PHD fingers suggest a role for
AIRE in transcriptional regulation. Two independent reports have shown that AIRE
can activate transcription in a GAL4-based reporter system (53,54). This
transactivation required the presence of more than one activation domain (54).
The possibility that AIRE interacts with the common transcriptional coactivator
CREB-binding protein (CBP) has been investigated. CBP is a transcriptional
coactivator for many transcription factors (55,56,57,58,59) has histone
acetyltransferase activity (60,61) and is localised in PML bodies (62). AIRE was
found to interact with CBP through the CHI and CH3 domains (54), two of CBP's
three domains putatively involved in protein-protein interactions.
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1.2.3 Regulation of AIRE expression
Until recently, the mechanisms by which AIRE gene expression is regulated were
unknown. However, in the last year, data regarding the promoter region of the AIRE
gene have been published (63). The AIRE promoter was found to contain a binding
site for activating protein-1 (AP-1) at -313 to -291 (63). AP-1 is a family of
transcription factors of homodimers and heterodimers of Jun and Fos or activating
transcription factor (ATF) proteins. Jun-Jun and Jun-Fos dimers bind to the TPA-
responsive element (TRE) and Jun-ATF and ATF homodimers bind the cAMP
responsive element (CRE). AP-1 is regulated through transcriptional control, which
determines the amount of AP-1 protein present, and by the modulation of its stability
through phosphorylation. In addition, the Jun proteins are regulated through
interactions with Jun kinases (JNK), as Jun is phosphorylated in response to JNK
activation. This phosphorylation enhances the ability of Jun to activate transcription
probably through an interaction with CBP (64). The AP-1 band seen in an EMSA,
was supershifted only by pan-Jun antibody, not pan-Fos antibody (63).
A CCAAT box was identified in the AIRE promoter, again by EMSA. This binding
on EMSA was confirmed to be binding of AIRE promoter to NF-Y protein, a protein
known to bind to the CCAAT box, by a supershift assay. The same techniques were
used to show that the GC box in the promoter was binding Spl (Specificity protein
1). The CCAAT box is present in 30% of eukaryotic promoters and NF-Y (also
known as CBF) is its major binding protein. Through binding between the protein
and the promoter, NF-Y is able to regulate gene transcription (65). Similarly, it is
well recognised that Spl binds to the GC box, and through this binding acts as a
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transcriptional regulator (66). Thus the promoter region of AIRE contains at least
three functional binding sites for common transcription factors.
In addition to binding by these transcription factors, AIRE gene expression is
regulated through gene methylation. The AIRE promoter contains a CpG island
which is approximately 300bp upstream of the translational start site and includes the
first exon, methylation of this region blocks the activity of the AIRE promoter (63).
Methylation of CpG islands is known to affect transcription, this is thought to occur
through either blocking the binding of transcription factors, or by the binding of
other proteins to the methylated residues which then prevent the access of
transcription factors to the DNA (67). In two monocytic cell lines (THP-1 and U937)
Aire was found to be heavily methylated, whilst a thymic epithelial cell line
(TEC 1 A3) was less heavily methylated (63), in keeping with the hypothesis that gene
methylation regulates the level of gene expression (67). Demethylation of these cell
lines up-regulated the expression of AIRE, indicating that methylation can silence
AIRE expression. Histone deacetylation was also shown to silence AIRE expression
(63).
1.2.4 AIRE functions as an E3 ubiquitin ligase
Following the observation that a subset of PElD-containing proteins is able to
mediate ubiquitin ligase activity, a Japanese group investigated the possibility that
AIRE also has this function. They have demonstrated that the first PHD domain of
AIRE does mediate E3 ubiquitin ligase activity, and that disease causing mutations
within this domain abolish this activity (68). The ubiquitin pathway participates in
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many functions of the cell including signal transduction, cell cycle progression and
apoptosis (69,70), all of which play a role in homeostasis of the immune system, thus
the elucidation of the target of ubiquitination by AIRE will be an important step
towards understanding the role of AIRE within the immune system.
1.2.5 Tissue distribution of AIRE
There are many reports in the literature describing the tissue distribution of Aire
using many techniques including RT-PCR, real time RT-PCR, in-situ hybridisation,
northern blot, western blot and immunohistochemistry in both humans and mouse.
There is discrepancy between these reports, thus the following discussion represents
a consensus based on the available information, further detail can be found in section
4.1.
Given the importance of Aire in the maintenance of tolerance, its expression within
the thymus has been investigated to gain insights into its function. Aire is primarily
expressed within the medullary epithelial cells (MEC) in a punctuate pattern, and at
the cortico-medullary junction, this expression is seen from E14.5 onwards (71,7,23).
In mice in which there is a failure of development of normal thymic architecture,
Aire transcripts could not be detected (71). This architectural organisation of the
medulla depends on signals from postselection thymocytes, which may be provided
by RelB. RelB deficient mice have medullary thymic atrophy, and do not express
Aire within the thymus (71,7). As it was postulated that Aire, by virtue of its
expression in an area involved in negative selection, is required for this process, the
expression of Aire in models of positive and negative selection was investigated. In
thymi from mice undergoing negative selection. Aire expression in the medulla and
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at the cortico-medullary junction was increased, whilst it was decreased in the
positively selecting mice (71).
In addition to expression in MEC, dendritic cells in the thymus and spleen have been
documented to express Aire, albeit at lower levels than in MEC (7).
Within the spleen, there is evidence for Aire expression in lymphocytes in the red
pulp in both humans and mice (51,6). However, this is disputed by Heino et al, who
attribute the mRNA expression detectable in the spleen to expression by splenic
dendritic cells (7).
In peripheral blood in humans and in mouse, Aire expression is seen in lymphocytes,
neutrophilic granulocytes and monocytes (51,6). Kogawa et al, examined AIRE
expression in purified populations of cells from human peripheral blood, and were
unable to detect Aire expression in CD4+ lymphocytes, but did see Aire expression
in CD 14+ cells (72).
There are many differences in the reported tissue distribution of AIRE, but taking all
the available data from both humans and mouse, there is some evidence to suggest
that AIRE is expressed in many peripheral tissues, including lung, testis, kidney,
ovary, adrenal gland, thyroid and gut (2,3,23,5,51,8,6,73,).
1.2.6 Insights into Aire function from knock-out mice
In the last year, two groups have published data on two different Aire deficient
mouse strains (13,74).
The first, published by Ramsey et al, has a targeted disruption of the Aire gene in
exon 6, and as such closely mimics the major Finnish mutation (74). These mice
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develop multiple organ specific autoimmune diseases and have circulating
autoantibodies. The major organs affected are the liver, which had periportal
accumulation of lymphocytes, the adrenal glands, which were atrophied, and the
ovaries, which were also atrophied. The thyroid and pancreas appeared normal (74).
No differences in T and B cell ratio or distribution were observed in the thymus,
lymph node or spleen, and no defect in T cell maturation within the thymus was seen.
The number of apoptotic thymocytes was unchanged, suggesting no difference in the
number of thymocytes undergoing negative selection. There was no evidence for an
increase in the number of activated lymphocytes, based on flow staining for CD62L
and CD44. Activation of cells from the lymph node via the T cell receptor (TCR)
using anti-CD3 antibodies revealed no difference in the up-regulation of the
activation markers, CD25 and CD69. The nai've phenotype of the T cells in the Aire
deficient mouse led to the suggestion that the mice had not been challenged as they
were housed in a sterile facility. Therefore, the response to immunisation was
assessed. The mice were immunised with hen egg lysozyme (HEL) in complete
Freund's adjuvant (CFA), followed by in vitro restimulation of draining lymph node
cells. The cells from the Aire deficient mice exhibited a 3-5 fold increase in
proliferation compared to wild type mice (74).
A mixed lymphocyte reaction using cells from Aire knockout and wild type mice
was used to determine whether normal tolerance to self was present. No proliferation
was detected in any of the combinations of cells used leading the authors to conclude
that tolerance to self and antigen processing by MHCII is normal and that this
experiment shows that "no major disturbances were evident to cause a difference in
thymic negative selection" (74). However, if autoreactive T cell clones were not
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deleted in the thymus, and are therefore present in the population of CD4 T cells
used in this MLR, it is probable that the clone would either be present at too low a
level allow a response to be seen, or that the APC used (CD4 depleted splenocytes)
would not stimulate the T cell clone present. Thus, although the statement quoted
above is true, I am not convinced that this experiment could be expected to
demonstrate the kind of difference they were looking for. To further determine
whether these mice have any alterations in lymphocytes, TCR VP chain usage was
assessed. No differences were observed in the thymus, but three out of 24 Vp
families were different in the spleen in Aire deficient mice compared to controls
(74). Based on these data the authors hypothesise that lack of Aire leads to a defect in
peripheral tolerance.
In contrast, Anderson et al, generated an Aire deficient mouse, in which the Aire
protein was truncated after exon 1 (13). Autoimmune disease was documented in the
salivary gland, ovaries or testis, thyroid, liver, stomach and retina in these mice;
circulating autoantibodies specific for these organs were also present. As with the
Aire deficient mouse generated by Ramsey et al, no differences in immune cell
numbers or distribution was seen. There were also no differences in lymph node cell
production of IL2, IL4 or IFNy, after stimulation with anti-CD3/28 antibodies.
However, an increase in the number of thymic MEC, and an increase in
activated/memory (CD44hlCD62Ll0) peripheral CD4+ and CD8+ cells was observed.
Further experiments in irradiated mice and in which Aire deficient thymi were
transplanted into athymic mice, lead to the conclusion that the presence of Aire in the
stromal cells of the thymus is necessary to prevent autoimmune disease in the
periphery (13). The issue of whether Aire expression in the target organs is required
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to prevent autoimmune disease was addressed. Transfer of Aire deficient
lymphocytes into wildtype mice lead to the development of autoimmune disease.
Thus the presence of Aire in these organs is not sufficient to prevent autoimmune
disease (13).
The role of Aire in the MEC of the thymus was then investigated, in particular,
whether Aire plays a role in the ectopic expression of peripheral antigens by these
cells. A substantial decrease in the number of genes expressed was observed in the
Aire deficient mice, with a bias towards ectopically expressed tissue specific
peripheral antigens. Therefore, Aire appears to play a role in central tolerance
through regulating the expression of peripheral antigens within the thymus (13).
The biological significance of this finding was confirmed in work by Liston et al.
They utilised the Aire knock-out mouse generated by Ramsey et al and crossed this
with a TCR transgenic mouse which expresses the TCR for a dominant peptide of
HEL which also expresses HEL under control of the rat insulin promoter (75). This
leads to expression of HEL in the pancreas and in small amounts circulating in the
periphery. This promoter has previously been shown to drive the ectopic expression
of peripheral gene in the thymus (76) and insulin is one of the genes whose thymic
expression is regulated by Aire (13). The authors were unable to demonstrate
expression of HEL protein in the thymus of Aire wild-type mice, however, a defect
in negative selection of HEL specific T cells was observed (75). Taking this data in
conjunction with that of Anderson et al, there is a strong argument for Aire playing a
role in central tolerance through driving the ectopic expression of peripherally
restricted antigens, and thus allowing negative selection of autoreactive T cells to
take place.
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Following the description of these two Aire knock-out mice, it was observed that the
phenotype was remarkably similar to that seen in the lymphotoxin-a (Lta) and the
lymphotoxin-P receptor (LTpR) deficient mice (77). In the Lta and LTpR deficient
mice, a 75-80% decrease in Aire expression was seen in thymus. This reduction in
Aire was enough to cause a decrease in the thymic expression of insulin, one of the
peripheral antigens under the control of Aire in the thymus. These mice had normal
thymic medullary epithelial cell development, but these cells expressed less Aire
than the wild types. In addition, thymic Aire expression is up-regulated by in vivo
treatment of both wild-type and Lta knock-out mice with an agonist LTpR antibody.
The down-regulation in Aire observed in the absence of the lymphotoxin pathway,
which leads to a decrease in the ectopic expression of peripheral antigens in the
thymus, was sufficient to cause a breakdown in tolerance, as evidenced by
autoantibody production (77).
1.2.7 Summary
Aire is required to prevent the development of autoimmune disease, but its presence
does not appear to be required in the target organs of autoimmunity to prevent
disease. Within the immune system, Aire is primarily expressed in the thymic MEC,
where it plays a role in directing the ectopic expression of tissue specific antigens,
thus allowing negative selection of autoreactive T cell clones. Further evidence for a
role for Aire in central tolerance, is provided by Park et al. In an in-vitro negative
selection system, inhibition of Aire using a dominant-negative construct increased
recovery rates of thymocytes, showing that Aire expression on the APC may play a
role in inducing thymocyte apoptosis (78).
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Aire is also expressed in peripheral lymphoid tissues. However, whether it has a role
in the peripheral immune system, is currently unclear.
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1.3 T cell activation and effector function
It is clear that Aire has a role in central tolerance, but the presence of Aire in the
peripheral immune system raises the question, what is its role here? The work in this
thesis was limited to examining the role of Aire in CD4+ T cells as it is these cells
that induce the broad range of effector functions that comprise peripheral immunity.
Thus the following discussion is primarily limited to CD4+ T cells.
1.3.1 T cell development
Immature double negative T cell precursors migrate from the bone marrow to the
thymus, where they enter into the cortex. Following TCR gene rearrangement, those
double positive thymocytes able to recognise self-MHC are positively selected.
During this process the double positive thymocyte becomes a single positive
thymocyte, with the co-receptor (i.e. CD4 or CD8) appropriate for the MHC type
against which the cell is selected being retained, and the other being lost. Those that
are not positively selected will die by neglect.
In addition to positive selection, developing T cells are negatively selected to select
out clones reactive against self-antigen. This process mainly occurs at the cortico-
medullary junction and within the medulla, although it could occur anywhere within
the thymus, if a self-peptide/MHC complex is recognised by the thymocyte. The self-
antigen/MHC complexes that mediate this process can be presented by DCs,
macrophages or medullary epithelial cells. The self-antigen is either internalised by
the DC/macrophage as it migrates to the thymus or is generated from apoptotic
thymocytes. The self-antigen present on thymic epithelial cells represents the ectopic
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expression of tissue specific genes, thus explaining the paradox of how T cells can be
negatively selected against tissue restricted antigens, these include insulin, glucagon,
glutamine acid decarboxylase (GAD) 65 and 67, thyroglobulin, thyroid peroxidase
and myelin basic protein (79,80,81). The expression of some of these antigens has
recently been shown to be under the control of Aire as described in section 1.2.6
(13).
1.3.2 T cell activation and development of effector phenotype
The mature, na'ive CD4+ T cell then leaves the thymus and circulates in the
peripheral blood passing through lymphoid tissue. Activation of naive CD4+ T cells
takes place in the lymphoid tissue upon encounter of the appropriate specific antigen
for that T cell on an APC expressing co-stimulatory molecules. Activation of a naive
T cell through the TCR alone, in the absence of co-stimulation will lead to anergy, a
state of inactivation that renders the cell unable to proliferate and differentiate into an
effector cell. In contrast, ligation of the TCR in the presence of co-stimulation,
usually provided by CD80 or CD86 on the APC signalling through CD28 on the T
cell, leads to activation and clonal expansion of the T cell. This requirement for co-
stimulation is important in tolerance to self antigens, as self antigens will generally
not be presented by an activated APC, therefore, this process ensures tolerance to
tissue specific antigens that are not expressed within the thymus.
Following TCR engagement in the presence of a co-stimulatory signal, the naive T
cell re-enters cell cycle and divides rapidly. The co-stimulatory signal, delivered via
CD28, promotes the synthesis of IL2, which drives these processes. Signalling
through the TCR leads to the generation of the transcription factor NFAT (nuclear
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factor of activated T cells) that binds to the IL2 promoter to activated transcription.
As cytokine mRNAs are inherently unstable, the stabilisation provided by the co-
stimulatory signal is important in increasing the synthesis of IL2. Co-stimulation
through CD28 ligation also induces NF-kB and AP-1, transcription factors that
increase IL2 transcription. In addition to an increase in IL2 production, synthesis of
the a chain of the IL2 receptor (CD25) is up-regulated, the association of the a chain
with the p and y chains increases the affinity of the receptor for IL2 and drives the
cell through the rest of the cell cycle. As well as up-regulation of CD25, the early
activation marker, CD69, is up-regulated in the activated T cell.
These proliferating T cells are then able to differentiate and adopt a specific effector
phenotype of T helper (Th) 1, Th2 or T regulatory (Treg) cell. This differentiation is
dependent on the cytokine milieu and co-stimulation by other molecules e.g. ICAM-
1/LFA-l, ICOS/B7, which is itself determined by the APC in response to the
conditions in which it first encounters the antigen it is expressing.
The effector phenotype of the T cell was first characterised by the cytokines
produced (82). Thl cells primarily secrete IL2, IFNy and TNFa and their major role
is to activate macrophages to allow killing of intracellular pathogens. The
differentiation into a Thl cell is directed by the presence of IFNy, which induces
expression of the transcription factor, T-bet (83) mediated by STAT1 (84).
The major role of Th2 cells is activation of B cells, leading to antibody production to
facilitate the clearance of extra-cellular pathogens. Their differentiation is induced by
the presence of IL4 (85) acting through STAT6 (86), leading to the up-regulation of
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the transcription factor GATA3 which regulates expression of many of the Th2
cytokines (87) including IL4 and IL5.
Differentiation of effector function occurring in the presence of IL10 and/or TGFp
leads to the development of T regs. A subset of Tregs can be characterised by their
surface expression of CD25 and in murine systems the transcription factor, Foxp3, is
required for the differentiation and function of Tregs.
1.3.3 The role of developmental gene pathways In mature T cells
As described above the presence of specific cytokines and transcription factors can
drive the differentiation of CD4+ T cells into different effector functions. However
there is increasing evidence that signalling through developmental pathways may
also contribute to this process. One of these pathways, the Notch signalling pathway
(described in detail in section 6.1.1), is recognised to have a role in the lineage
decisions of developing T cells, and more recently interest has turned to the role of
this pathway in mature T cells.
In 2000, Hoyne et al demonstrated that presentation of antigen by DCs in the
presence of the Notch ligand, Serrate, induces the development of a regulatory
population of T cells, which are able to transfer tolerance (88). More recently, it has
been shown that up-regulation of the Notch pathway, by overexpression of one of the
ligands (Jagged), induces the development of functional antigen specific regulatory T
cells (89). The same is true of overexpression of one of the Notch receptors
(Notch3), when regulatory T cells are generated which are able to protect against the
development of experimental autoimmune diabetes (90). Signalling mediated by a
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specific ligand-receptor combination (Delta-likel and Notch3) has been shown to
generate a Thl phenotype (91). Thus, there is evidence to suggest that Notch
signalling may play a role in determining the effector phenotype of T cells.
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1.4 Summary
Aire plays a role in central tolerance to self antigens, but the role of Aire in the
peripheral immune system remains to be elucidated. However, following recent
evidence regarding the importance of transcription factors in the development of T
cell effector function, it is tempting to speculate that Aire, which is also a
transcription factor, may have a role in T cell effector function.
Thus, the hypothesis of this work was that lack of functional Aire affects peripheral
T cell function. In order to test this the following aims were addressed.
1. Characterisation of the phenotype and genotype of patients with APS1 in the
UK
2. Investigation of whether there are differences in peripheral lymphocyte
subsets and in the T cell proliferative response in APS1 patients compared to
controls.
3. Characterisation of the tissue and cellular distribution of Aire mRNA and
protein in the adult and embryo.
4. Characterisation of the expression of Aire in immune cell subsets and the
effect of activating these cells on Aire expression.
5. Investigation of an interaction between Aire and the Notch signalling





All reagents were obtained from Sigma (Poole, Dorset, England) unless otherwise
stated.
2.1 Patient Recruitment
The initial cohort of patients was recruited by Dr S Pearce, by writing to all
endocrinologists in the UK to ask if they were aware of any patients with APS1.
Following this patients were referred to Dr Pearce and myself for mutational analysis
to enable a diagnosis of APS1 to be made.
2.2 DNA extraction
DNA was extracted from lOmls of whole blood collected into an EDTA tube. The
DNA was extracted using the Nucleon BACC2 kit (Amersham Biosciences, UK).
Briefly, cells were lysed as per the manufacturers instructions and deproteinised with
sodium perchlorate. Chloroform and Nucleon resin was used to extract the DNA,
which was precipitated from the aqueous layer with absolute ethanol. The resulting
DNA was resuspended in TE buffer and the DNA concentration quantified using a
photospectometer.
2.3 AIRE mutational analysis
All patients were screened for the common UK mutation, 964dell3, and the major
Finnish mutation, R257*, by PCR and restriction digest. Novel mutations were
51
sought by single strand conformational polymorphism (SSCP) analysis of all 14
exons.
2.3.1 PCRof AIRE
Genomic DNA was used as a template for PCR utilising primers (Table 2.1) that
encompassed each of the 14 exons ofAIRE. PCR was performed with 200ng DNA,
50 pmol of each primer, 200pM dNTP's, ImM MgC^, 50mM KC1, lOmM Tris-HCl
(pH 8.3) and 1 U Taq DNA polymerase (Gibco BRL) in a final volume of 50pl. An
initial denaturation step at 94°C for 5 minutes was followed by 35 cycles of
amplification, each cycle consisted of 30 s at 93°C, 30 s at a primer pair dependent
annealing temperature (see Table 2.1) and 30 s at 72°C. After these 35 cycles, a final
extension step of 72°C for 5 min was performed. PCR products were run out on a
1.5% agarose gel, and visualised with ethidium bromide.
2.3.2 Screening for the common UK mutation 964del13
PCR of exon 8 was performed as described above yielding a product of 229bp
(Figure 2.1). The resulting PCR product was digested with the restriction enzyme,
BsrBI, the restriction site for which is abolished in the presence of the 964dell3
mutation (Figure 2.2). Thus, digest of the wild type sequence gives 2 products, 140








































































Figure 2.1 PCR of genomic DNA for exon 8 of AIRE












Figure 2.2 A The 13bp deletion in exon 8 abolishes the BsrBl
restriction site. B Map of restriction products from digest of wild-type
and mutant products. C Results of restriction digest of PCR product
from wild-type, mutant and a compound heteroygote.
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2.3.3 Screening for the common Finnish mutation R257*
PCR of exon 6 was performed as described to give a product of 303bp (Figure 2.3).
The resulting PCR product was digested with the restriction enzyme, Taql, one of
the restriction sites for which is abolished in the presence of the R257* mutation
(Figure 2.4). Thus, digest of the wild type sequence gives 3 products, 171, 62 and 72
bp, whilst if the mutant sequence is present 2 products of 171 and 134 bp are seen
(Figure 2.4).
2.3.4 SSCP to identify novel mutations in AIRE
Following analysis for the two common mutations as described above, there
remained unidentified alleles. DNA from these patients was subject to PCR for exons
1,2,3,6,7,8,9,10,11 and 14, as described in section 2.3.1. The PCR products were
analysed for SSCPs using precast 12.5% polyacrylamide gels that were run on the
Phast minigel electrophoresis system (Pharmacia LKB), for 150-185 V-h at 10°C.
The gels were then fixed in an aqueous solution of 10% ethanol and 0.5% acetic acid
and stained with a 0.1% aqueous silver nitrate solution for 30 minutes. After two
washes in dFFO, the colour was set using an aqueous solution of 1.5% sodium
hydroxide and 0.15% formaldehyde for 20 minutes and fixed in ImM EDTA.
Samples from patients known not to have mutations in the exon concerned were
included on all gels as a control.
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Figure 2.3 PCR of genomic DNA for exon 6 of AIRE




Figure 2.4 Genotyping for the common Finnish mutation
R257* A Map of restriction products from digest of wild-type and
mutant products. B Results of restriction digest of PCR product from a
wild-type and a compound heteroygote.
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2.4 Determination of MHC haplotype
The presence/absence of a non-Aspartate 57 allele (HLA DQB*0201,0302,0501 and
0604) or the "protective" HLA DQB*0602 was determined by low resolution HLA
typing using primers supplied by the Blood Transfusion Service (Newcastle upon
Tyne). Further high resolution typing was carried out by the Blood Transfusion
Service (Newcastle upon Tyne). HLA typing on an additional 7 patients was
performed using an HLA-DQB high resolution kit from Protrans (Quest Biomedical,
Solihull, UK) as per the manufacturers instructions.
2.5 Determination of IDDM2 alleles
The IDDM2 locus is the variable number of tandem repeats in the 5' polymorphic
region of the insulin gene. This was examined utilising the Hphl polymorphism,
which is effectively in complete linkage disequilibrium (0.002 recombination rate)
with the INS VNTR alleles (92,93). Genomic DNA was amplified by PCR using
oligonucleotide primers to produce a 440bp fragment (Fig 2.5). The primer
sequences were 5' - TCC AGG ACA GGC TGC ATC AG - 3' and 5' - AGC AAT
GGG CGG TTG GCT CA - 3'. PCR was performed with 250 ng of DNA, 200pM of
dNTP's, 0.75 mM of MgCb, lx PCR buffer and 1U of Taq DNA polymerase (Life
Technologies Inc., Paisley, UK) in a final volume of 50pl. After an initial
denaturation at 94°C for 5 minutes, 28 cycles of PCR amplification were performed,
with each cycle consisting of 1 minute at 94°C, 1 minute at 58°C and 1 minute at
72°C. The PCR product was digested overnight at 37°C with the restriction enzyme
Hphl. This yields fragments of 240bp and 160 bp in patients homozygous for the A
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allele; 280bp and 160bp in patients homozygous for the B allele and 160bp, 240bp
and 280bp in heterozygotes. These fragments were resolved by electrophoresis on a
2% agarose gel (Fig 2.5). The A allele at the Hphl polymorphism is carried on the
same haplotype as the Class I VNTR alleles, and the B allele is on the class III
VNTR haplotype. Because of the near complete disequilibrium between alleles of the
Hphl SNP and the VNTR genotypes, the A and B alleles have been considered as








Figure 2.5 Determination of INS VNTR allele A PCR of
exon 6 B Restriction digest with Hphl gives products of 160,
240 and/or 280bp
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2.6 Isolation of human peripheral blood cells
Blood was collected for isolation of peripheral cells into a heparinised tube from
APS1 patients, controls and normal volunteers.
2.6.1 PBMCs
Blood was collected from APS1 patients and controls. After dilution in an equal
volume of PBS, the blood was layered onto Histopaque, and centrifuged at lOOOg for
20 minutes. The cloudy interface containing the PBMCs was removed and the cells
washed in PBS prior to counting on a haemocytometer.
2.6.2 Adherent cells
Blood was collected from healthy volunteers, diluted in an equal volume of PBS and
layered onto Histopaque and centrifuged as described above. Following removal of
the PBMCs these were resuspended in serum-free media (Complete RPMI minus
serum) at 107cells/ml and incubated in a 75cm2 flask for 60 minutes in a humidified
incubator, 37°C 5% CO2. After this culture period, the cells were washed with PBS
to remove any non-adherent cells, and the adherent cells were removed using a cell
scraper.
2.7 Staining of human cells for flow cytometry
Human PBMCs were isolated as in section 2.6.1, all staining was performed in a 96
well round bottom plate. 5xl05 cells were added to each well in a final volume of
200pl of FACS buffer, the antibodies and isotype controls used can be found in table
2.2. The combination of antibodies used together is shown in table 2.3. After staining
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for 30 minutes, the cells were washed twice using FACS buffer and resuspended in
lOOpl of FACS buffer and lOOpl of FACS fix prior to analysis on a FACSCalibur
flow cytometer (Becton Dickinson) using CellQuest Software (Becton Dickinson).
The appropriate isotype controls and single stains were used to optimise the settings
prior to each run.
Antibody to Fluorochrome Manufacturer
CD3/4/8 PECy5/PE/FITC Dako
TCR-ap FITC BD Pharmingen
TCR-y5 FITC BD Pharmingen
CD19 FITC Dako
CD8 FITC BD Pharmingen
CD45RO FITC Dako
Va24 FITC Dako
CD94 PE BD Pharmingen
CD45RA PE Dako
CTLA-4 PE BD Pharmingen
CD69 PE Dako
CD8 PECy5 Dako
HLA-DR CyChr BD Pharmingen
CD25 PE-Cy5 Dako
CD4 APC BD Pharmingen
IgM FITC BD Pharmingen
IgG2a FITC BD Pharmingen
IgGa PE Dako
IgG2a PE Dako
IgGlK CyChr BD Pharmingen
IgGlK APC BD Pharmingen
Table 2.2 Anti-human antibodies and isotype control
antibodies used for flow cytometry
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FITC PE CyChr/PE-Cy5 APC
Isotype
control Isotype control Isotype control Isotype control
CD8 CD4 CD3
TCR-ap CD94 CD8 CD4
TCR-y8 CD94 CD8 CD4
CD19 CD45RA HLA-DR
CD8 CD69 CD25 CD4
CD45RO CD45RA CD25 CD4
CD8 CTLA4 CD25 CD4
Va24 CD94 CD8 CD4
Table 2.3 Antibodies used for phenotyping peripheral cell
subsets in APS1 patients. The table shows the combinations of
fluorochrome antibodies used, details of the method used are in
section 2.7
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2.8 Human PBMC proliferation assay
Human PBMCs were isolated as in section 2.6.1 and added to 96 round bottom well
plates, previously coated with anti CD3s antibody (O.lpg/ml or lpg/ml) alone or
with plated bound anti-CD3s plus anti-CD28 antibody (lpg/ml), at 2.5xl05
cells/well. Cells were cultured in CM. Cells were incubated in a humidified
incubator, 37°C 5% CO2. At 48 hours the plates were pulsed with 0.5pCi of tritiated
thymidine and harvested 16 hours later. Plates were read using a liquid scintillation
counter Betaplate 1205 (Wallac, Milton Keynes, UK).
2.9 Cytokine analysis of supernatants from stimulated
human PBMCs
The concentrations of IL2, IL4, IL5, IL10, IFN-y and TNF-a were determined using
a Human Thl/Th2 CBA (cytokine bead array) kit as per the manufacturers
instructions. Briefly, samples and standards were incubated with detection beads for
3 hours then washed in wash buffer followed by centrifugation at 300g for 5 minutes.
The beads were then resuspended in wash buffer prior to analysis on a FACSCalibur
(Becton Dickinson) with CellQuest software.
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2.10Animals used
CDl, BALB/c and C57BL/6J mice (B&K, Hull, England) were housed in the
University of Edinburgh Animal Facilities in accordance with local guidelines.
Embryonic tissue was taken at embryonic (E) days 14.5, 16.5 and 18.5 from time-
mated pregnancies, where embryonic day 0 (EO) was determined by detection of the
vaginal plug.
2.11 Tissue coilection
Mice were sacrificed in accordance with Home Office guidelines. Tissue for in-situ
hybridisation was collected into an RNase free tube on dry ice and stored at -70°C
until required. Tissue for RNA extraction was collected into Trizol in an RNase free
tube on ice and stored at -70°C until required. Tissue for immunohistochemistry was
fixed in 4% buffered formalin and processed into paraffin blocks. Tissue for protein
extraction was stored at -20°C until required.
2.12 Determination of RNA expression
2.12.1 RNA extraction
RNA was obtained from whole tissues and cells by extraction using Trizol (Life
Sciences, Paisley, UK), as per the manufacturers instructions. Tissue samples were
homogenised first using an electric homogeniser. Briefly, chloroform was added and
the samples centrifuged at 13000g for 15 minutes. The aqueous RNA containing
layer was removed and the RNA precipitated using isopropyl alcohol. The pellet was
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obtained by centrifugation at 13000g for 10 minutes, and then washed in 70%
ethanol. After drying the pellet was resuspended in nuclease free water and
quantified using a spectrophotometer. All samples were DNase treated using RQ1
RNase free DNase (Promega, Southampton, UK) in accordance with the
manufacturers instructions. To ensure that there was no residual DNA contamination,
the RNA was used in a PCR with primers for the housekeeping gene, (3-actin. The
lack of a PCR product was consistent with no DNA contamination. In one reaction,
DNA was used rather than RNA to check the PCR reaction had worked. The reaction
mix used was lx buffer, 100pM dNTPs, 20pmol primers, 2.5mM MgCU, 0.5U Taq
and 50ng RNA. The reaction conditions were 94°C for 2 minutes followed by 30
cycles of 94°C for 30 seconds, 58°C for 1 minute, 72°C for 2 minutes with a final
denaturation step of 94°C for 2 minutes. Primer sequences are F 5"-CCA CCA ACT
GGG ACG ACA TG, R 5^-GTC TCA AAC ATG ATC TGG GTC ATC which yield
a 153bp product.
2.12.2 RT-PCR
RNA (2pg) was reverse transcribed in a reaction containing lx buffer, 5mM MgC^,
ImM dNTPs, Oligo dT primers (1:20), RNase inhibitor (1:40) and RT (1:20).
Reaction conditions were 42°C for 30 minutes then 99°C for 5 minutes, the resulting
cDNA was stored at -20°C prior to use in the PCR reaction.
5 pi of cDNA was used as the template for PCR with primers to amplify a 418bp
fragment of murine Aire. The reaction contained lx buffer, ImM MgC12, ImM
dNTP's, 5pmol/pl primers, 0.05%W-1 and 1U Taq (Gibco), reaction conditions were
96°C for 3 minutes followed by 30 cycles of 96°C for 45 seconds, 56°C for 30
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seconds and 70°C for 90 seconds. (Primers; F -AAG AAG CCA GAT GGC AAC
TT; R -CGA GGA TGA GTG TGC CGT GT) (nucleotide numbers 550-569 and
948-967; accession number NM 009646.1)
2.12.3 in-situ hybridisation
Generation of cRNA probe
Aire was amplified from mouse thymus by RT-PCR as described above and 3 pi of
this PCR product was cloned into PGEMTeasy vector (Promega) by an overnight
incubation at 4°C with T4 DNA ligase (Promega). 2pl of this ligation reaction was
used to transform competent cells (JM109) by heat shock at 42°C for 45 seconds.
These cells were plated out overnight on ampicillin containing LB plates and
colonies were picked the following day. An individual colony was used in a 5 ml
starter culture of LB that was incubated overnight at 37°C. The plasmid was obtained
from 1.5ml of this starter culture using Promega Wizard SV miniprep kit as per the
manufacturers instructions. The presence of the insert was confirmed by restriction
digest with EcoRl (Promega). Following this 2ml of the starter culture was used in a
100ml culture from which the plasmid was obtained by midiprep using the Promega
Wizard Plus Midiprep DNA purification system as per the manufacturers
instructions. The insert was confirmed by sequencing and the orientation by
restriction digest with Ncol (Promega). The plasmid was cut with Sail to generate
the template for the anti-sense probe and with Aatll to generate the template for the
sense probe. After restriction digest the plasmid was extracted with
phenol/chloroform. Sense (control) and anti-sense 35S labelled RNA probes were
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generated from this plasmid using SP6 and T7 RNA polymerase respectively.
Briefly, a reaction containing lx buffer, 1U of RNA polymerase (SP6 or T7), lOmM
DTT, RNase inhibitor, 1.5mM ATP, 1.5mM CTP, 1.5mM GTP, 20pM UTP, 5pM
35S UTP and lpg of template. This reaction was incubated for 90 minutes at 37°C
(T7) or 40°C (SP6) followed by DNase treatment with Dnasel (Promega). The probe
was purified by passing through a Nick column (Amersham), counted in a (3 counter
and stored at -70°C until required.
in-situ hybridisation (ISH)
Tissue was obtained from 6-8 week old CD1 mice, and C57BL/6J embryos. Frozen
sections (10 microns) were cut and mounted onto poly-l-lysine coated slides.
Sections were fixed in 4% paraformaldehyde, washed in PBS and acetylated (0.25%
acetic anhydride in 0.1M triethanolamine, pH8.0). After prehybridisation in a SSC
humidified chamber, the sections were hybridised at 50°C overnight with 35S
labelled probe (lx 107 cps/slide) in a SSC humidified chamber. Slides were washed
then RNase treated for 1 hr at 37°C, followed by further washes and dehydration in
alcohol. Slides were dipped in Kodak NTB2 emulsion (Kodak, Hemel Hempstead,
UK) and developed 2 weeks later. Tissue was counterstained with haematoxylin and
eosin, then coverslipped.
2.12.4 Real Time RT-PCR
A Taqman based system and ABI Prism 7700 sequence detector was used for real
time RT-PCR. This system utilises the 5"exonuclease activity of Taq polymerase and
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FRET (Fluorescent Resonance Energy Transfer). A fluorescently labelled probe
which has a high energy reporter and a low energy quencher is used in addition to
primers. When the probe is intact, energy transfer ensures that the probe does not
fluoresce (FRET). The probe used anneals to the cDNA between the two primers,
and as the primer is extended by the Taq polymerase its exonuclease activity cleaves
the probe. As the quencher and the reporter are no longer in close proximity, the
amount of fluorescence increases.
All reagents were obtained from Applied Biosystems (Warrington, UK). Reverse
transcription was performed using the Multiscribe RT™ kit and random hexamer
primers, as per the manufacturers instructions. Briefly 400ng of RNA was reverse
transcribed in a reaction containing lx TaqManRT buffer, 5.5 mM MgCE, 500pM
dNTP's, 2.5pM Random Hexamers, 0.4U/pl RNase inhibitor, 1.25U/pl MultiScribe
RT, at 25°C for 10 minutes, 48°C for 45 minutes and 95°C for 5 minutes.
Primers were designed using Primer Express for murine Aire (F - 5'CCT GGA TTT
CTG GAG GAT TCT CT3" (nucleotides 282-304); R - 5'CCG TCC AGG ATG CTA
TGC A3 "(nucleotides 339-356); Probe - 5"6FamCGG CTG TAC CGC TCC AGA
TTG TAG TCC T Tamra3"(nucleotides 308-335)) (Sequence accession number
NM 009646.1), and murine Hesl (F - 5GGC TTT TCG GTG ACC CAT CT3"; R -
5"CGC GGT ATT TCC CCA ACA3"; Probe - 5"6FamTTC TCC TTC TGG CCT
GCA GCC G Tamra3") and PCR was performed using Taqman Universal PCR
Master Mix™ with 300nM primers and 200nM probe plus lx 18S primer/probe as an
internal calibrator for each sample. All samples were run in triplicate. Data were
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analysed using the comparative CT method (Applied Biosystems). cDNA from whole
thymus from an adult CD1 mouse was used as a positive control for all runs
involving expression within tissue; in experiments involving the in-vitro culture of T
cells, the media control sample was used as the calibrator; all mRNA levels were
determined in relation to the calibrator sample.
• TThe comparative C method uses the cycle number at which the fluorescence
increases above baseline, the cycle threshold (CT). This value is obtained for both the
gene of interest and the internal control (18S) and one is subtracted from the other to
give the change in cycle threshold (ACT) to compensate for small differences in
loading. This value is then normalised against the designated calibrator in the
experiment (AACT). The following calculation is then carried out 2~AACT, this gives a
value of 1 to the calibrator sample and all other samples as a fold change in gene
expression compared to this.
2.13 Determination of Protein Expression
2.13.1 Antibodies used
A rabbit polyclonal anti-human AIRE antibody (designated 2328.1) was raised by Dr
S Pearce (University of Newcastle upon Tyne), by giving 6 injections of a peptide
consisting of AIRE amino acids 147-165 conjugated to BSA. The immunoglobulin
(Ig) was then Protein A purified from serum as per the manufacturers instructions
(HiTrap Protein A affinity column, Amersham Pharmacia Biotech, Bucks, England).
For some experiments, the Aire antibody was FITC conjugated using a FluoroTag kit
(Sigma); the molar fluorescence/protein ratio of the conjugated antibody was 3.2.
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The anti-PSPl antibody was a kind gift from Prof A Lamond, University of Dundee.
2.13.2 Characterisation of anti-AIRE antibody
Western blotting of murine thymic protein with the rabbit polyclonal anti-human
AIRE antiserum (Section 2.13.5) revealed a band of the expected molecular weight
of Aire (58kDa) (Fig 4.6). The amino acid sequence of the peptide used for
immunisation is homologous between mouse and human at 11 out of 19 amino acids.
Specificity in mouse was further confirmed by immunohistochemistry (Section
2.13.7), in control sections by preabsorption with peptide in excess, and incubation
of additional control sections with Protein A purified Ig from preimmune serum (Fig
2.6). Staining was within the nucleus in a punctate pattern, consistent with the
subcellular expression previously reported (51).
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Fig 2.6 Immunohistochemistry of murine thymus.
A Negative control; B Incubated with Aire antiserum; C
Incubated with preimmune serum; D Incubated with Aire
antiserum preabsorbed with peptide.
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2.13.3 Protein extraction
Cells were resuspended in protein lysis buffer (approx 106 cells in 200pl), followed
by sonication on ice for 30 seconds in 5 second bursts, followed by protein
quantification. For extraction of protein from tissue, a small amount of tissue was
homogenised in protein lysis buffer. Following centrifugation at 13000g for 5
minutes the supernatant was removed and the amount of protein contained quantified
as described below.
As Aire is a nuclear protein expressed at low levels, to increase the yield of Aire
protein, protein was extracted from nuclei only. Cells were resuspended in nuclear
lysis buffer at l-2xl08/ml, passed through a 25G needle and centrifuged at 1800g for
15 minutes at 4°C. The resulting pellet was resuspended in the same amount of
nuclear lysis buffer and sonicated for 30 seconds on ice in 5 second bursts, quantified
then stored at -20°C until required.
2.13.4 Protein Quantification
Protein content was estimated using a BCA kit (Biorad) as per the manufacturers
instructions. Briefly, 50pl of sample or standard was added to 2 ml of Biorad protein
assay reagent inverted to mix and incubated at room temperature for 15 minutes. The
absorbance at 595nm was read in a spectrophotometer. The absorbance was plotted
against the concentration of the BSA standards using Excel to generate a standard
curve from which the values for the samples were derived.
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2.13.5 Western blotting
Proteins were resolved on a 10% SDS/acrylamide separating gel, overlaid with a 4%
stacking gel. For blots with protein extracted from tissue, 30pg of protein was loaded
per well, for blots with immunoprecipitated proteins 5pi of the immunoprecipitated
protein was loaded per well. Gels were run at 100 volts for 2 hours and then
transferred onto a nitrocellulose membrane at 150 volts for 30 minutes. After
blocking with 5% SMA for hungry babies in TBST for 2 hours the membrane was
incubated with primary antibody overnight at room temperature (anti-Aire antiserum
1:50 for tissue, 1:150 for immunoprecipitated protein; anti-PSPl antibody 1:2000;
both in 5% SMA for hungry babies in TBST). The membrane was then washed 3x15
minutes in TBST followed by incubation with goat anti-rabbit HRP antibody (Dako)
at 1:2000 in TBST for 2 hours at room temperature. An ECL plus kit (Amersham
Biosciences) was used as the chemiluminescent substrate, this was detected using
ECLplus radiographic film (Amersham) and developed using an Xograph Compact
X4.
2.13.6 Immunoprecipitation
lpg of protein was precipitated using 2 pg of antibody in a final volume of 1ml with
PBS plus protease inhibitor cocktail and ImM sodium orthovanadate (lysis buffer).
This was incubated at 4°C for 1 hour, following which 30pl of Protein A-sepharose
was added for a further 1 hour at 4°C. This was washed with 1 ml of ice cold lysis
buffer 3 times; each wash was followed by centrifugation at 13000g for 5 minutes at
4°C. After a final centrifugation the beads were resuspended in 25pi of 2x sample
buffer and 25 pi of 10% SDS, and stored at -70°C until required. Prior to use
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samples were boiled for 5 minutes to dissociate the protein from the antibody, this
was followed by centrifugation at 13000g for 5 minutes to spin down the beads, the
supernatant was then loaded onto an SDS/polyacrylamide gel as described in section
2.13.5.
2.13.7 Immunohistochemistry (IHC)
All IHC was performed on a Biogenex Optimax plus automated staining system
(Biogenex, Berkshire, UK). Tissue was taken from C57/BL6J and CD1 mice into 4%
buffered formalin then processed into paraffin blocks. Three pm sections were cut
and mounted on Vectabond treated slides (Vector Laboratories, Peterborough,
England). Slides were dewaxed in xylene, and rehydrated. Antigen retrieval
consisted of microwaving the sections at 1000W for 3x5 minutes in Vector antigen
retrieval solution (Vector Laboratories) that was diluted 1:100 in deionised water.
Slides were blocked with 2% hydrogen peroxide for 15 minutes, washed then
blocked with 20% goat serum. The AIRE antibody was preabsorbed with 20% mouse
serum and 20% goat serum overnight at 4°C. Slides were incubated with primary
antibody or preimmune serum (0.675ng Ig/slide) or primary antibody that had been
pre-incubated with the peptide used to raise the antibody (peptide was used at lOx
excess), for 2 hours at room temperature, washed, incubated with a goat biotinylated
anti-rabbit secondary antibody (1:400) (DAKO, Ely, Cambridgeshire, UK), washed
then Vector RTU ABC (Vector Laboratories) was applied and positive signal was
detected by the addition of diaminobenzidine (DAB) (DAKO). The slides were
counterstained with haematoxylin and coverslipped. Avidin/biotin blocking
(Avidin/Biotin blocking kit, Vector Laboratories) was used on all tissues.
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2.13.8 Immunofluorescence
For all immunofluorescence, cells were resuspended at 10 cells/ml in PBS, 5pl was
added to each slide (Superfrost plus, BDH, Poole Dorset UK) and smeared into a thin
film, air dried, fixed in 90% dry acetone/ 10% methanol for 10 minutes, washed in
PBS then blocked with Dako diluent (Dako) for 10 minutes.
For single stains, the slides were incubated with primary antibody, washed and
incubated with secondary antibodies (See table 2.4 for antibodies used). All
incubations were at room temperature for 30 minutes. Slides were then incubated
with ToPro3 (Molecular Probes) diluted 1:200 in PBS for 10 minutes to allow
visualisation of the nucleus. Slides were coverslipped using Mowiol mounting
medium. Images were captured using a Leica TCS NT confocal system (Leica
Microsystems, GmBH Mannheim, Germany). Control slides which had no primary
antibody added to them were included in each experiment.
Primary antibody Secondary antibody Tertiary antibody
Anti-Aire (1:50) Goat anti-Rabbit ~ (1:100) Donkey anti-Goat 568*(1:200)
Anti-Hesl (1:30) # Donkey anti-Goat 568*(1:200)
Table 2.4 Antibodies used for single stains
~
Dako
*Molecular Probes, Leiden, The Netherlands
# Santa Cruz Biotechnology, Santa Cruz, California
For double staining for Aire and PSP1, slides were stained with the antibodies shown
in table 2.5. All incubations were for 30 minutes at room temperature except for that
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with Aire-FITC that was at 4°C overnight. Slides were washed with PBS between
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Table 2.5 Double staining of cells for Aire and PSP1
For double staining with Aire and other nuclear proteins, slides were first stained for
Aire as described above for a single stain, this was followed by incubation with
either anti-PML antibody (1:10), anti-sc35 antibody (1:1000) or anti-coilin antibody
(1:100), all antibodies were a kind gift of Prof A Lamond, Dundee. After washing
with PBS, the slides were incubated with goat anti-mouse Alexa 488 (Molecular
Probes). For double staining with Aire and cell surface markers, slides were first
stained for Aire as described above for a single stain, this was followed by incubation
with FITC conjugated cell surface marker (anti-CD4, 8 or IgDb, Pharmingen) (1:10),
washed, incubated with mouse anti-FITC antibody (1:10), washed then incubated
with goat anti-mouse Alexa 488 (Molecular Probes) (1:200). All incubations were
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for 30 minutes at room temperature, after the final wash cells were counterstained
with ToPro3 and coverslipped as described above.
2.14Cellular isolation from murine spleen
Spleens from C57BL/6J or BALB/c mice were mechanically disrupted by being
ground through a 40pM cell strainer in PBS to give a single cell suspension. The cell
suspension was centrifuged at 300g for 7 minutes and the resulting pellet was
resuspended in 4mls of red cell lysis buffer plus 1ml of cold PBS, incubated on ice
for 3 minutes after which 1 Omls of cold PBS was added followed by centrifugation at
300g for 7 minutes. The cells were counted using a haemocytometer with trypan blue
exclusion.
The cell type required e.g. CD4+, CD19+, was then isolated using MACS beads
(Miltenyi Biotech, Germany) as per the manufacturers instructions. For positive
selection kits (CD 19), the splenocytes were resuspended in 90pl of MACS buffer
plus lOpl of antibody micro-beads per 107 cells and incubated at 4°C for 15 minutes.
The cells were washed by adding an excess of MACS buffer and pelleted by
centrifugation at 300g for 7 minutes. The cell pellet was resuspended in 500pl of
o
MACS buffer per 10 cells and cell separation was performed on an AutoMACS
machine (Miltenyi Biotech, Germany) using a Possell program. For negative
selection kits, e.g. CD4+ and Pan T cell, the splenocytes were resuspended in 40pl of
MACS buffer plus 1 OjlxI of Biotin-Ab cocktail and incubated at 4°C for 10 minutes. A
further 30pl of MACS buffer was added plus 20pl anti-biotin beads per 107 cells
followed by incubation at 4°C for 15 minutes. The cells were washed by adding an
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excess of MACS buffer and pelleted by centrifugation at 300g for 7 minutes. The cell
- 8 •
pellet was resuspended in 500pl of MACS buffer per 10 cells and cell separation
was performed on an AutoMACS machine (Miltenyi Biotech, Germany) using a
Deplete program.
Cells were then counted using a haemocytometer with trypan blue exclusion. 6x10'
cells were kept for FACS analysis to check the cell purity (Section 2.18), the
remainder were used for culture.
2.15Culture of CD4+ T cells
2.15.1 Activation with anti-CD3 and anti-CD28 antibodies
Murine CD4+ T cells were cultured in complete media at 2xl06/ml in 24 well plates
(96 well plates for proliferation assays). The plates were first coated with anti-CD3s
antibody, 1ml (lOOpl for 96 well plates) of anti-CD3s antibody at O.lpg/ml was
added to each well and incubated for 2 hours at 37°C. The plates were then washed
with PBS to remove any unbound antibody. Cells were plated out at the density
described above plus soluble anti-CD28 antibody (1 or 5pg/ml). The cells were
incubated in a humidified incubator, 37°C 5%CC>2, for 24, 48 or 72 hours and then
harvested.
2.15.2 Co-culture with Delta-likel expressing L cells
Delta-like 1 (Dll) expressing L cells (A kind gift from Prof M Dallman, Imperial
College, London) were used in co-culture experiment with murine CD4+ T cells. The
Dll L cells and the parental L cells were cultured in HAT media, with geneticin
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selection for the Dll L cells. Once the cells were sub-confluent, trypsin and EDTA
was used to remove them from the flask, once the cells were lifted from the flask the
trypsin/EDTA was inactivated by the addition of CM, the cells were then washed in
CM and counted using a haemocytometer.
Prior to co-culture the cells were mitomycin C treated, 0.5mg of mitomycin C in
lOmls CM was added to the L cells, and cells were incubated at 37°C for 1 hour.
Following this the cells were washed 3 times in CM prior to counting. The cells were
then plated out in complete media at 2xl03/ml and C57BL/6J CD4+ T cells were
added at 2xl06/ml in a final volume of 2mls in 24 well plates and 200pl in 96 well
plates and incubated for 24 hours in a humidified incubator, 37°C 5%C02.
2.16Proliferation assay - murine CD4+ T cells
Murine CD4+ T cells were cultured in 96 round bottom well plates as described in
Section 2.15. Cells were incubated in a humidified incubator, 37°C 5%C02, for 24,
48 or 72 hours. Sixteen hours prior to the end of the culture period, the plates were
pulsed with 0.5pCi of tritiated thymidine. At the end of the culture period the plates
were harvested, then read using a liquid scintillation counter Betaplate 1205 (Wallac,
Milton Keynes, UK).
2.17CFSE staining of CD4+ T cells
All tubes were wrapped in foil to prevent fading of the CFSE. A stock solution of
ImM CFSE was made up in DMSO. CD4+ T cells were resuspended at 107/ml in
PBS and incubated at 37°C for 10 minutes, followed by the addition of luM CFSE.
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Cells were stained for 15 mins at 37°C, then lOOul of HI FCS was added per ml of
cells to inactivate the CFSE. Cells were washed twice in complete media at 300g for
7 minutes.
Following the culture period, cells were stained with anti-CD4-PE antibody, as
described in Section 2.18, and analysed the same day.
As CFSE staining was used to confirm the absence of cell division, a positive control
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Fig 2.7 CFSE staining of antiCD3/CD28 activated T
cells. A Dot plot showing the lymphocyte gate; B Dot plot
gated on the lymphocyte gate showing the CD4+ cell gate; C
Histogram gated on CD4+ cells demonstrating division of the
proliferating cells by CFSE staining.
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2.18Analysis of murine cell surface molecule expression by
flow cytometry
Flow cytometric analysis was carried out on a FACSCalibur (BD Pharmingen).
2X103 cells were added to each well of a 96 well plate in a final volume of 200pl of
FACS buffer plus 10% mouse serum (Scottish Antibody Production Unit) and either
0.5pg of FITC labelled or 0.2pg of PE labelled antibody (see table 2.6 for details of
antibodies used). The cells were incubated in the dark at 4°C for 30 minutes. Cells
were washed twice in FACS buffer and resuspended in lOOpl of FACS buffer and
lOOpl of FACS fix and stored at 4°C for a maximum of 3 days.
Antibody Fluorochrome Isotype Manufacturer
Anti-CD4 PE RIgG2bK BD Pharmingen
Anti-CD25 FITC rlgMx BD Pharmingen
Anti-CD69 PE HsIgG BD Pharmingen
Anti-CD3 PE HsIgGl eBioscience
Anti-CD 19 PE BD Pharmingen
Table 2.6 Antibodies used for cell surface marker identification
in mouse
The amount of apoptosis was assessed by flow cytometry using an AnnexinV/7AAD
kit (BD Pharmingen) as per the manufacturers instructions.
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2.19 Materials
Complete HAT Culture Media ± Geneticin: RPMI 1640 with 10% HI FCS,
lOOU/ml penicillin/streptomycin (Gibco), 2mM L-glutamine (Gibco), 15pg/ml
hypoxanthine (Gibco), 0.2pg/ml aminopterin (Gibco), 5pg/ml thymidine (Gibco),
6jig/ml mycophenolic acid and 250pg/ml xanthine ± 500pg/ml geneticin (Gibco).
Kept at 4°C.
Complete RPMI culture media (Human): RPMI 1640 with 10% heat
inactivated (HI) foetal calf serum (FCS), 50pM P-mercaptoethanol (ME), lOOU/ml
penicillin/streptomycin (Gibco), 2mM L-glutamine (Gibco). Stored at 4°C.
Complete RPMI Culture Media (Mouse): RPMI 1640 with 10% HI FCS,
lOOU/ml penicillin/streptomycin (Gibco), 2mM L-glutamine (Gibco). Stored at 4°C.
DEPC H2O: Add 5 drops of diethyl pyrocarbonate to 500mls dH20.
FACS buffer: 0.5% BSA, 0.1% NaN3 in PBS.
FACS fix: 4% paraformaldehyde in PBS
y-secretase inhibitor: The g-secretase inhibitor II (MW167) (Merck Biosciences,
Darmstadt, Germany) was dissolved in lOmM DMSO to give a final concentration of
1 mM.
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2x hybridisation buffer (for in-situ hybridisation): 1.2M NaCl, 20mM Tris
(pH7.5), 2x Denhardts solution, 2mM EDTA, 2mg salmon sperm DNA, 2g dextran
sulphate, 2mg yeast tRNA in DEPC H2O. Aliquot and store at -20°C.
LB: 2.5g Yeast, 5g Tryptane, 5g NaCl make up to 500ml with dH20 and pH with
NaOH to pH7.5. Autoclave the same day.
LB agar: As for LB above plus 7.5g Agar. To pour plates melt LB agar by heating,
allow to cool to hand hot and add ampicillin (50pg/ml). Pour plates and allow to set.
MACS buffer: 0.5% BSA in PBS
Mowiol mounting medium: 2.4g of Mowiol is added to 6g glycerol and stirred
briefly with a pipette, then 12ml of dH20 is added followed by stirring at room
temperature overnight. The following day, 12ml of 0.2M Tris (pH 8.5) is added then
heated to 50°C for l-2hours whilst stirring. Once the Mowiol has dissolved, clarify
by centrifugation at 5000x g for 15 mins. DABCO was added to 2.5% and aliquots
were stored at -20°C.
Nuclear protein lysis buffer: 0.01M Hepes, O.lmM EGTA, 0.5mM PMSF,
lOmM KC1, 0.04mM DTT, ImM MgCl2, lx Protease inhibitor in dH20.
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4 x pH 8.8 buffer: 1.5M Tris, 0.4% SDS in dH^O, autoclave and store at room
temperature.
4 x pH 6.8 buffer: 0 .5M Tris, 0.4% SDS in dFEO, autoclave and store at room
temperature.
2x prehybridisation buffer (for in-situ hybridisation): 1.2M NaCl, 20mM
Tris (pH7.5), 2x Denhardts solution, 160|uM EDTA, lOmg salmon sperm DNA, 2mg
yeast tRNA in DEPC H2O. Aliquot and store at -20°C.
Protein lysis buffer: 50mM Tris pH7.5, 0.32M Sucrose, ImM EDTA pE18, lx
Protease inhibitor cocktail, ImM PMSF in dhEO.
Red cell lysis buffer: ImM NH4HCO3, 114 mM NH4C1 in dH20
5 x Running buffer: 0.12M Tris, 1M Glycine, 0.5% SDS in dH20
2x sample buffer: 50mM Tris pH6.8, lOOmM DTT, 2% SDS, 0.1% bromophenol
blue, 10% glycerol in dPEO. Store at -20°C.
20xSSC: 3M NaCl, 0.3M Trisodium citrate in dH20, pH to 7.
10% separating gel: 10% polyacrylamide, pH 8.8 buffer plus 0.05% APS and
0.05% TEMED.
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4% stacking gel: 4% polyacrylamide, pH 6.8 buffer plus 0.05% APS and 0.1%
TEMED
TBST: 0.9% NaCl, lOOmM Tris pH7.5 in dH20 plus 0.01% Tween 20.




3 Characterisation of APS1 patients in the UK
3.1 Introduction
The absence of functional AIRE, as seen in patients with APS 1, causes a wide spread
defect in self-tolerance, as evidenced by the development of multiple autoimmune
diseases (4). APS1 most frequently manifests in early childhood. The first endocrine
component occurred as early as 19 months of age in a large Finnish series, with
additional disease manifestations developing throughout life (4). Forty three percent
of these Finnish patients had 4 or more disease manifestations (4). A variety of
different mutations in AIRE are present in patients with APS1 (2,3,1,15,17) either
homozygously or in combination with another mutation in AIRE i.e. compound
heterozygote. There is no genotype-phenotype correlation, and at the present time,
prediction of the development of new manifestations or complications of APS 1 is not
possible (1).
Type 1 diabetes and APS1
Type 1 diabetes (T1D) occurs in 12-18% of Finnish APS1 patients (4,43). T1D as a
disease has a significant impact on an individual's health, thus the ability to predict
its development would be advantageous. In 1999, Ward et al described 2 siblings
with APS1 who were discordant for T1D, and suggested that the IDDM2 locus may
have role in the development of the T1D associated with APS1 (94). This led to work
considering the role of this locus in APS1 patients in the UK.
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The effect of non-functionai AIRE on T cell function
Aire is known to be important in central tolerance as demonstrated in murine
experimental models (13,75), where it is required to delete organ specific T cells
within the thymus (75). However, the role of Aire in peripheral T cell function is less
well understood. Given that diabetes, in common with the other autoimmune diseases
seen in APS1, is T cell mediated, it seems logical to consider the effect non¬
functional AIRE has on T cell function. Ramsey et al noted that the lymphocytes of
an Aire knockout mouse have an uncontrolled proliferative response when re-
challenged in vitro with HEL compared to wild type littermates (74), suggesting that
Aire may have a role in regulating the immune response in the periphery, but at
present there are no data in the literature on how lack of Aire affects the function of
peripheral lymphocytes from APS1 patients.
The aims of this chapter were
1. to characterise the phenotype and genotype of patients with APS1 in the UK
2. to determine whether diabetes susceptibility can be predicted in UK APS1
patients
3. to investigate whether there are differences in peripheral lymphocyte subsets




Patients with APS1 in the UK were sought as described in 2.1. 13 patients formed the
original cohort. These patients were genotyped by Dr S Pearce in Newcastle prior to
the start of this thesis (1). The remaining patients were genotyped in Newcastle
where this thesis was commenced. 33 British APS1 patients were studied; the mean
age was 24.2 years, range 9-56, with 24 males and 9 females. These patients were
members of 28 unrelated kindreds with subjects 5 and 27, 9 and 13, 10 and 12, 11
and 15 and 19 and 21, being full siblings (Table 3.1). Diagnosis in the proband of a
family was based on the presence of at least two out of three cardinal features,
chronic mucocutaneous candidiasis (CMC), primary hypoparathyroidism and
primary adrenal failure. In a sibling of an index case, one of the cardinal features was
sufficient for the diagnosis of APS1 (4).
29 of the 33 patients (80.56%) had primary hypoparathyroidism, 28 (77.78%) had
chronic mucocutaneous candidiasis, 23 (63.89%) Addison's disease, 9 (25%)
gonadal failure, 8 (22.22%) type 1 diabetes, 8 (22.22%) malabsorption, 6 (16.67%)
hepatitis, 4 (11.11%) alopecia, 3 (8.33%) keratopathy and 3 (8.33%) ectodermal
dystrophy. In addition, the following manifestations were present in individual
patients, ankylosing spondylitis, hypothyroidism, red cell aplasia, diabetes insipidus,
pernicious anaemia, hypertension, epilepsy, cataracts, gallstones and pulmonary
fibrosis.
The majority of patients with APS1 have multiple manifestations of the syndrome,
representing a significant disease burden for the individual patient.
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23 of the 33.patients (70%) studied here have 4 or more manifestations of APS1 (Fig
3.1), compared to 43% of Finnish APS1 patients (4).
This difference is most likely because APS1 is more readily recognised in the
genetically isolated population of Finland where it is much commoner. Thus, due to
this greater awareness patients may be diagnosed with less manifestations of the
disease than here in the UK where a patient with CMC and Addison's may not




HP* AD* CMC* T1D* Other
1 M 10 Y Y M,H
2 M 15 Y Y Y Y
3 M 20 Y Y Y Y A,T
4 M 24 Y Y Y Y GF
5 M 33 (sib of 27)" Y Y Y Y A
6 M 37 Y Y Y M, RCA, OC
7 M 41 Y Y Y Y M,GF, K, PA
8 F 52 # Y Y Y Y GF
9 M 9 (sib of 13) Y Y Y N
10 F 10 (sib of 12) Y Y N
11 M 10 (sib of 15) Y N
12 M 13 (sib of 10) Y N H
13 M 12 (sib of 9) Y Y Y N M
14 F 13 Y Y N
15 F 13 (sib of 11) Y Y N M,H,P, K
16 M 14 Y Y N
17 F 15 Y Y Y N H
18 M 15 Y N H,Ch
19 F 16 (sib of 21) Y N
20 M 17 Y Y Y N M,GF
21 M 19 (sib of 19) Y Y Y N H,GF
22 M 20 Y Y Y N M,GF
23 M 23 Y Y N
24 F 26 Y Y Y N M,T
25 F 26 Y Y Y N GF
26 M 26 Y Y Y N T
27 M 26 (sib of 5)" Y Y N
28 M 27 Y Y Y N
29 M 36 Y Y N
30 F 37 Y Y Y N GF,AS
31 M 37 Y Y Y N A,GF
32 M 51 Y Y Y N A,K
33 M 56 Y Y Y N A
Table 3.1 Clinical Characteristics of UK APS1 patients
*Y= present, N= absent.
HP - Hypoparathyroidism; AD - Addisons disease; CMC - Chronic
mucocutaneous candidiasis; T1D - Type 1 diabetes; M - Malabsorption; K-
Keratopathy; A - Alopecia; GF - Gonadal Failure; H - Hepatitis; AS- Ankylosing
Spondylitis;
T - Hypothyroidism; RCA - red cell aplasia; PA - Pernicious anaemia;
Ch - Cholelithiasis; P - Pulmonary fibrosis, OC - Oral Carcinoma; C - Cataracts.
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No. of manifestations
Figure 3.1 Number of manifestations of APS1 per
patient
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3.3 AIRE mutations present in APS1 patients
Mutational analysis of the original cohort of patients by Dr Pearce showed that the
commonest mutation in the UK is 964dell3 (71% of mutant alleles) (1), whereas in
the Finnish population the mutation R257* predominates (85% of mutant alleles)
(2,3).
The common UK mutation, designated 964dell3, is a 13bp deletion in exon 8 which
gives rise to a non-functional AIRE-1 protein of 372 amino acids, truncated at the
start of the first zinc finger motif. The major Finnish mutation is a nonsense mutation
in exon 6, R257*. This encodes a non-functional 256 amino acid protein, truncated in
the SAND domain and containing neither zinc finger.
All patients were screened by PCR and restriction digest for 964dell3 and R257* as
described in section 2.3 (Table 3.2). The common UK mutation 964dell3 was
present in 31 of the 33 patients (94%), accounting for 46 of the 66 alleles (70%) as
15 of these patients are homozygotes for this mutation, the remainder being
compound heterozygotes. This is in accordance with previously reported findings
(1). In addition, 3 of 33 patients were heterozygous for the Finnish major mutation
R257*, accounting for 3 out of 66 alleles (4.5%).
There remain 11 unidentified alleles in 11 patients. One of these patients was from
the original cohort and therefore had already been screened for a second mutation by
SSCP. The DNA from the remaining 10 patients was subject to PCR and SSCP
(Section 2.3.4) targeted at the exons where mutations in AIRE cluster. The exons
96
screened were exons 1, 2, 3, 6, 7, 8, 9, 10, 11 and 14. No novel mutations were
identified.
AIRE mutation AIRE mutation AIRE mutation
1 964dell3 + Un 12 964dell3 + Un 23 964dell3 + R257*
2 964dell3 + Un 13 964dell3 + Un 24 964dell3x2
3 *964dell3x2 14 964dell3x2 25 *964dell3x2
4 *964dell3x2 15 #964dell3x2 26 964del 13 + Un
5 *964dell3x2 16 *964dell3x2 27 *964dell3x2
6 *xl0del + L28P 17 964dell3x2 28 964dell3x2
7 *964dell3x2 18 964dell3 + Un 29 *R257* + Y90C
8 *964dell3 + Un 19 *964dell3 + R15L 30 *964dell3 + xlOdel
9 964dell3 + Un 20 964del 13 + Un 31 964del 13 + Un
10 964dell3 + Un 21 *964dell3 + R15L 32 964dell3x2
11 #964dell3x2 22 964dell3x2 33 964dell3 +R257*
Table 3.2 Aire mutations in UK APS1 patients
The common UK and Finnish mutations, 964dell3 and R257* were screened for
using PCR and restriction digest, novel mutations were sought using SSCP
♦original cohort of patients (l)
mutational analysis on these patients was carried out by Dr S Pearce
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3.4 The prediction of diabetes susceptibility in patients with
APS1
Type 1 diabetes (T1D), an autoimmune disease which has multiple susceptibility
genes, was reported to occur in 12 to 18% of Finnish APS1 patients (4,43). The pre¬
clinical phase of T1D is characterised by the presence of autoantibodies, however not
all those with autoantibodies will go on to develop T1D. In keeping with this,
autoantibodies against glutamic acid decarboxylase (GAD) occur more commonly
than T1D, being present in 32% of APS1 patients (46), although the positive
predictive value of GAD65 antibodies for T1D in APS1 is only 27% (43). Recently it
has been suggested that antibodies against the IA-2 tyrosine phosphatase-like protein
(IA-2 ab) or insulin (IAA) are better markers of active beta cell loss with a positive
predictive value in APS1 patients of 67% for T1D (30). Therefore, none of these
measurements alone are sufficient to predict diabetes development in APS 1 patients.
The genetic susceptibility loci that contribute the most to diabetes susceptibility are
the major histocompatibility complex (MHC) class II genes designated IDDM1, and
insulin gene polymorphisms (IDDM2) (95). In view of the reported association
between IDDM2 and diabetes susceptibility in a sibpair, this study to define the
relationship between IDDM1 and 1DDM2 and the presence of T1D in a larger group
of APS1 patients was undertaken.
3.4.1 Type 1 diabetes and IDDM1 in UK APS1 patients
In T1D, IDDM1 contributes 50% of the genetic risk (96). Of the MHC class II genes,
HLA DQB and in particular residue 57, determines susceptibility to (or protection
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from) type 1 diabetes. Of the MHC class II genes, HLA DQB1*0201 and 0302
alleles are the main predisposing alleles for type 1 diabetes in a non-APSl
population, with compound heterozygosity for these alleles being present in 30% of
type 1 diabetes patients (97). In addition a non-Asp residue at position 57 of the
DQ[3-chain on either DQB allele is present in 98% of type 1 diabetes patients (98). In
contrast, HLA DQB 1*0602 protects against the development of type 1 diabetes (99).
Unlike other autoimmune polyendocrinopathy syndromes, there are no known HLA
associations with the cardinal manifestations of APS1. However, Gylling et al.
recently suggested that HLA DQP 1*0602 may be associated with protection against
the development of T1D in an APS1 population (30).
HLADQB typing (section 2.4) was performed on 25 APS1 patients, 5 of whom have
diabetes (Table 3.3). Two of these 5 with type 1 diabetes had a "non-aspartate 57"
DQB allele. Of the 20 APS1 patients without type 1 diabetes, 7 had a non-aspartate
57 allele (p=0.6, Fisher's exact test). None of the 5 APS1 patients with diabetes
carried HLA DQB*0602, however 4 of 20 non-diabetic APS1 patients (20%) did.
This difference was not significant (p=0.38).
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APS1 with T1D (%) APS1 without T1D (%)
Non-Asp57 allele present 2(40)+ 7(35)
Non-Asp57 allele absent 3 (60) 13(65)
HLA DQB*0602 present 0 (0) f+ 4(20)
HLA DQB*0602 absent 5 (100) 16(80)
Table 3.3 HLA status of APS1 subjects with and without Type 1
diabetes
HLA DQP typing was performed utilising PCR to determine the presence or
absence of a non-Asp57 allele (as described in section 2.4).
Non-Asp57 alleles are HLA DQB*0201,0302,0501 and 0604, and are present
in 98% of non-APSl type 1 diabetes.
fp=0.6, Fisher's exact test.
f tp=0.38, Fisher's exact test.
APS1 with T1D (%) APS1 without T1D(%)
Hphl AA homozygotes 6(75)+ 8 (32)
Hphl AB or BB 2(25) 17(68)
Table 3.4 Hphl genotypes in APS1 subjects with and without Type
1 diabetes
Hphl genotype was ascertained by PCR and restriction digest.
AA is equivalent to homozygous class I INS VNTR alleles and is a T1D
susceptibility genotype in non-APSl subjects. AB and BB are equivalent to a
class I/class III heterozygote and class III homozygote (T1D protective
genotypes), respectively,
f p=0.042, Fisher's exact test.
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3.4.2 Type 1 diabetes and IDDM2 in UK APS1 patients
The 5' polymorphic region of the insulin gene (INS), located on chromosome
11 pi5.5, consists of a variable number of tandem repeats (VNTR) and determines
susceptibility to T1D (IDDM2) (93,92). This INS gene polymorphism can be divided
into three classes depending upon the number of repeats: the class III allele of the
INS gene is dominantly protective for T1D, whereas homozygosity for the class I
allele predisposes to T1D (relative risk 1.9-5.0) (92).
Patients were screened by PCR and restriction digest to determine which IDDM2
allele was present as described in section 2.5. Eight out of the 33 (24%) APS1
subjects had T1D. Of the 8 with T1D, 6 (75%) were homozygous for the Hphl A
allele, which is in tight linkage disequilibrium with the T1D susceptibility class I
VNTR (Table 3.4). In comparison, only 8 out of 25 (32%) APS1 patients without
T1D were homozygous for the A allele (OR=6.4, [5-95% CI =1.2-34.7]; p=0.042
Fisher's exact test). The 2 APS1 patients with T1D, who did not carry the
homozygous A allele (subjects 4 and 6), were aged 37 and 24 years, respectively.
The mean age of the subjects with T1D was 29 (range 10-52) compared to 22.6
(range 9-56) in the APS1 patients without T1D. This older age in the T1D group
leaves open the possibility that further cases of T1D may develop in the unaffected
APS1 cohort as they age.
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3.4.3 Patient genotype-phenotype - Conclusions
The difficulty experienced in predicting new disease manifestations in APS1
combined with the observation that insulin gene polymorphisms segregated with
T1D in one sibpair (94) lead to the investigation of this in 33 APS1 subjects from the
U.K. In this relatively small cohort, there is an increase in the frequency of INS
VNTR Class I associated alleles in those subjects with type 1 diabetes compared to
those without type 1 diabetes (75% vs. 32%, p=0.042). This suggests an association
between the development of type 1 diabetes and homozygosity for Class I INS
VNTR in patients with APS1, which is similar to that seen in the non-APSl type 1
diabetes population. Previous studies have shown that 73% of non-APSl type 1
diabetes patients are homozygous for the class I VNTR, this figure is remarkably
similar to the 75% AA genotype in the APS1 type 1 diabetes patients studied here
(92). However, this work clearly demonstrates that INS gene polymorphisms are not
necessary disease alleles for the development of type 1 diabetes in the UK APS1
population.
AIRE is known to be expressed in thymic medullary epithelial cells, its expression is
up-regulated in models of negative selection (7,8,71,6) and the ectopic expression of
insulin within the thymus is under the control of Aire (13). In addition, there is
differential expression of insulin within the thymus of diabetics with the different
INS VNTR haplotypes. Homozygosity for class I alleles is associated with low levels
of insulin, but the protective class III allele is associated with high levels of insulin
(80,81). Positive and negative selection of thymocytes can be affected by the
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concentration of peptide presented, with higher concentration of peptide leading to
negative selection and lower concentrations to positive selection (80). This
relationship between IDDM2 and type 1 diabetes is in keeping with this, however, if
thymic expression of insulin is under the control of Aire in humans as seen in the
Aire knock-out mouse (13), then insulin would not be expressed in the thymus
irrespective of the insulin gene polymorphism present. If this is the case, then it
seems unlikely that the positive relationship between lack of diabetes and a
protective IDDM2 allele would exist. Thus it may be that, unlike the Aire knock-out
mouse, thymic expression of insulin is not under the control of AIRE in humans.
Alternatively, in APS1 insulin may not be the primary autoantigen, but
autoantibodies to insulin may appear after tissue damage has occurred mediated
through an alternative autoantigen, e.g. GAD.
As in previous studies, no association with a "susceptibility" HLA haplotype was
found (100). Gylling et al (100) documented an absence of the protective HLA
DQB*0602 in APS1 patients with diabetes, whilst non-diabetic APS1 patients
showed a significant increase in the prevalence of this haplotype. The results of this
work are entirely consistent with this finding.
AIRE plays a role in negative selection within the thymus through the ectopic
expression of tissue restricted antigens and the appropriate negative selection of T
cells specific for these antigens (13,13,75). In addition, the differential expression of
self-peptides in the thymus leads to the regulation of negative selection (80). Thus,
the observation of a positive relationship between INS polymorphisms and type 1
diabetes in APS1 is consistent with this mechanism of action of AIRE.
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3.5 Characterisation of peripheral lymphocytes in APS1
patients
There are a limited number of reports in the literature of studies on the phenotype or
biological function of lymphocytes in patients with APS1 (42,101,102,103,104). To
date, there are no data in the literature regarding the proliferative response of T cells
from patients with APS1 compared to controls, and limited inconclusive data on
alterations in peripheral cell subsets (42,104,103). However, the peripheral control of
any autoreactive T cells which exit the thymus is important in preventing
autoimmune disease, and the autoimmune diseases that occur in APS1 are T cell
mediated. Therefore, the phenotype and biological function of peripheral
lymphocytes was investigated in a small number of APS1 patients.
3.5.1 Comparison of peripheral lymphocyte subsets in patients and
controls
In 1991, Friedman et al investigated 9 patients with APS1 and found no evidence for
a difference in T or B lymphocyte or NK cell populations by flow cytometric
staining for CD3, CD4, CD8, CD20, CD5 and CD56 compared to the percentages of
these populations in normal children (42). More recently, Sediva et al examined a
similar selection of markers in 4 patients with APS1. Two out of 4 patients had
elevated numbers of CD4+CD3+ T cells, no other differences were found (103). The
lymphocyte subpopulations of 6 patients with CMC, 2 of whom had APS1 were
investigated, no difference in CD4+ or CD8+ T cells was observed (104).
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This study analysed peripheral blood cell subsets in patients with APS1 in
comparison to age and sex matched controls using a wide panel of antibodies.
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by
centrifugation through a Ficoll gradient (Section 2.6). The PBMCs were stained for
analysis by flow cytometry with antibodies to cell surface markers (Section 2.7;
Table 2.2). Populations of T, B and natural killer T (NKT) cells were delineated
using antibodies for CD3, CD19 and CD94 respectively (Figs 3.8, 3.9). CD3+ T cells
were then stained for CD4 and CD8 or TCR ap and y8 (Fig 3.8). CD4+ T cells were
further subdivided using antibodies against CD45RA and CD45RO to determine the
proportions of naive and memory cells, and CD25, CD69 and CTLA4 to assess the
activation status of the cells. CD8+ T cells were also stained for CD25 and CD69 and
CTLA4. CD 19+ B cells were stained for CD45RA and HLA-DR. NKT cells were
subdivided on CD4 and CD8 and Va24. Data for cells stained with CTLA4 and
Va24 was not analysed, as this staining was comparable to that obtained with the
appropriate isotype control due to the low numbers of resting cells that express these
markers. Representative flow cytometry data for one patient (Figs 3.3, 3.5, 3.7) and
one control (Fig 3.2, 3.4, 3.6) are shown. No significant differences in cell surface
marker expression were seen in patients compared to controls (Figs 3.8-11) in the
initial cohort of 2 patients and 3 controls. As this initial data revealed no differences,




















































Fig 3.2 Representative FACS plots - Control
A PBMC's from whole blood, with lymphocyte gate (Rl)
B Isotype controls gated on Rl
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Fig 3.3 Representative FACS plots - Patient
A PBMC's from whole blood, with lymphocyte gate (Rl)
B Isotype controls gated on Rl













































































Fig 3.4 Representative FACS data - Control
A Lymphocytes; B B cells; C NKT cells
All histograms are gated on gate R1 (lymphocytes) and the gate for
the corresponding dot plot is shown on the histogram
The antibodies used are described in section 2.7 and in table 2.3
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Fig 3.5 Representative FACS data - Patient
A Lymphocytes; B B cells; C NKT cells
All histograms are gated on gate R1 (lymphocytes) and the gate
for the corresponding dot plot is shown on the histogram
The antibodies used are described in section 2.7 and in table 2.3
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Fig 3.6 Representative FACS data - Control
Characterisation of A CD4 and B CD8 subsets. All histograms
are gated on gate R1 (lymphocytes) and the gate for the
corresponding dot plot is shown on the histogram/dot plot
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Fig 3.7 Representative FACS data - Patient
Characterisation of A CD4 and B CD8 subsets. All histograms
are gated on gate R1 (lymphocytes) and the gate for the
corresponding dot plot is shown on the histogram
The antibodies used are described in section 2.7 and in table 2.3
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3.5.2 Characterisation of the response to T cell receptor stimulation in
APS1 patients
Prior to this thesis, there was no information regarding the proliferative response of
human T cells lacking AIRE to stimulation through the T cell receptor. Data from the
Aire deficient mouse shows an increased proliferative response to an in-vitro
rechallenge with HEL (74). Kobrynski et al, investigated 6 patients with CMC, 2 of
these had APS1. These 2 APS1 patients show a trend to higher proliferation to PHA
compared to those with CMC (104).
The response of peripheral blood mononuclear cells to stimulation by anti-CD3 and
anti-CD28 antibodies was examined in 3 patients with APS1 and 3 controls. Briefly,
PBMCs were isolated as described above and plated into 96 well plates in the
presence of varying concentrations of anti CD3 and anti CD28 antibodies for 48
hours. Sixteen hours prior to the end of the culture period the cells were pulsed with
tritiated thymidine, the incorporation of which was subsequently assessed (Section
2.8).
The patients with APS1 have a higher background proliferation than controls and a
trend to a higher maximal proliferative response (Figure 3.12A). However, there was
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Fig 3.12 Response of PBMCs to stimulation with anti
CD3/28 antibodies in APS1 patients and controls.
A Proliferation as assessed by incorporation of tritiated thymidine
B Stimulation index
All data are represented as the mean +/-SD (n=3 per group)
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3.5.3 Cytokine secretion by activated human PBMCs
There is limited information on the cytokine profile of peripheral lymphocytes from
APS1 patients. Sediva et al, show a trend to decreased IFNy production by activated
PBMCs from APS1 patients compared to controls (103). Additionally, patients with
isolated CMC, which is one of the cardinal features of APS1 produce less IFNy in
response to candidal antigens than controls (105,106).
PBMCs were isolated and plated out as described in section 3.5.2, and supernatants
were collected at 48 hours for measurement of cytokines. Levels of IFNy, TNFa, IL-
10, IL-5, IL-4 and IL-2 were determined using a human Thl/Th2 cytokine bead array
(CBA) kit (BD) (Section 2.9). There was no significant difference in cytokine
secretion between the patients and controls (Figs 3.13 and 3.14). In view of this and
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Fig 3.13 Cytokine secretion by patient and control
PBMCs in response to anti-CD3 and anti-CD28
antibodies is similar. Individual patients(d)/controls (o) are
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Fig 3.14 Cytokine secretion by patient and control
PBMCs in response to anti-CD3 and anti-CD28
antibodies is similar. Individual patients(D)/controls (O) are
represented by separate data points, the mean is represented by
the bar
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3.5.4 Patient T cell function - Conclusions
It is difficult to draw any firm conclusions from this limited data set, even when
taken in conjunction with the other data available. However, it seems probable that
patients with APS1 have no perturbation in peripheral lymphocyte subsets. There are
currently 2 published Aire deficient mice, one of these is designed to mimic the
major Finnish mutation by targeted disruption of exon 6, and these mice have no
differences in peripheral cell subsets (74). The other Aire deficient mouse has a
deletion of exon 2 giving rise to a protein truncated after exon 1. These mice have
normal CD4/CD8 subset distributions but an increase in CD44hlCD62Ll0 CD4+ and
CD8+ T cells (13). This difference in the 2 different Aire deficient mice may
represent a difference in the generation of the mice. The strain generated by
Anderson et al, which has an increase in activated/memory cells, has an Aire protein
consisting of just exon 1. This compares to the strain generated by Ramsey et al
which has an Aire protein truncated in exon 6, in which no differences are seen in the
proportion of activated cells. This is unlikely as there is no phenotype-genotype
correlation in APS1, and by extrapolating from data in transactivation studies neither
of these proteins would be expected to be functional (54). Alternatively the disparity
in activated cells present may be due to, as Ramsey et al state, the fact that their mice
have not been challenged as they are housed in a sterile facility. However, as no
difference was observed in CD44 and CD62L expression, in Aire deficient mice
compared to wild-type mice, after an in-vitro re-challenge with HEL, this
explanation would also seem unlikely (74).
The situation in patients is further complicated by the fact, that unlike the Aire
deficient mice, they are all on varying combinations of treatment for the
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manifestations of APS1 that will affect T cell function. In particular, the patients
studied here were all on glucocorticoid replacement therapy, oestrogen replacement
and Vitamin D3. Glucocorticoids are immunosuppressive and may therefore affect
the proliferative response to anti-CD3 and anti-CD28, they are known to inhibit the
production of all the cytokines investigated here and can promote the development of
a Th2 phenotype (107). Vitamin D3 may also promote Th2 responses (108), whereas
oestrogens can lead to increased antigen specific T cell responses and a skewing to a
Thl phenotype as evidenced by increased interferon y production (109). Thus, it is
not surprising that the data on PBMC proliferation and cytokine production, and
resting lymphocyte subsets is equivocal.
3.6 Summary
In keeping with previous studies documenting the phenotype of APS1 patients (4),
UK patients have a significant disease burden. Being able to predict new disease
manifestations would significantly improve the management of patients with APS1.
However, although there is a positive relationship between the IDDM2 locus and
type 1 diabetes in APS1, it does not enable the absolute prediction of diabetes
susceptibility.
Patients with APS 1 have no differences in cell surface marker expression compared
to controls, and although there is a trend to higher background proliferation, the fold
change in proliferation and cytokine secretion from stimulated PBMCs is no
different. Thus, no firm conclusions could be drawn from these data due to the small
number of patients readily available for study, the heterogeneity of the disease and





4 Expression of Aire in adult and embryonic murine tissues
4.1 Introduction
The pattern of human AIRE mRNA expression was first described in 1997 by 2
independent groups (2,3). Northern analyses showed mRNA expression in thymus,
lymph node and fetal liver. AIRE expression was also reported in spleen and tissues
affected in APS1, such as adrenal cortex and pancreas by one group (2), but not by
another (3). Human AIRE protein expression, as determined by
immunohistochemical staining, was seen in thymic medulla, lymph node, spleen and
fetal liver (51,8) but expression was not observed in tissues other than these (8).
Reports of the tissue distribution of murine Aire mRNA are also discordant.
Although Aire mRNA could not be detected by northern blot analysis (23,5,73), RT-
PCR revealed the presence ofAire transcripts in heart, lung, testis (23,8,73), thymus
(7,6,73) and lymph node (7,6). There are conflicting reports of Aire mRNA
expression in spleen (23,7,73), kidney, brain (23,6), and liver (6,73). A single report
founds/re mRNA in ovary, adrenal gland and thyroid (73).
Aire protein has been found in adult thymic medullary epithelial cells (7,6,74), and in
thyroid, gut, pancreas and brain (7,74). Aire protein expression in spleen, lymph
node, adrenal gland, lung, ovary, liver, kidney and testis is discordant between
studies (7,6,74).
In the murine embryo, Aire expression can be seen using RT-PCR, in-situ
hybridisation and immunohistochemistry from embryonic day 14.5 in thymic
medullary epithelial cells (23,5,7).
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Characterising the normal distribution of Aire is crucial to the understanding of its
role in maintaining self-tolerance. However, it is clear, there is a lack of consensus
regarding the tissue distribution of Aire, and variability in expression as determined
by the same technique between studies. Therefore, a comprehensive survey of Aire
mRNA expression using RT-PCR, in-situ hybridisation and real time RT-PCR, and
protein using immunohistochemistry was undertaken in adult murine tissues to
clarify this issue. In addition, protein expression in the whole embryo was
investigated, as to date Aire expression has only been described in the embryonic
thymus.
The aims of this chapter were
1. to characterise the tissue distribution of Aire mRNA and protein in the adult.
2. to characterise the tissue distribution of Aire mRNA and protein in the
embryo.
3. to assess differences in level of mRNA expression between the embryo and
adult
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4.2 Expression of Aire mRNA in tissues of adult mice
The tissue distribution and level of mRNA expression in adult mice was investigated
using RT-PCR, in-situ hybridisation and real time RT-PCR.
4.2.1 RT-PCR
Initial characterisation of mRNA expression was performed on thymus, spleen, liver
and 2 of the target organs in APS1 pancreas and adrenal gland, from the out-bred
strain CD1, as described in section 2.12.2. Expression was seen in thymus and weak
expression was seen in the spleen (Fig 4.1 A).
4.2.2 in-situ hybridisation
To gain information regarding spatial distribution, in-situ hybridisation was
undertaken on tissues from CD1 mice. Using this relatively insensitive method,
expression could only be determined in the adult thymic medulla (Fig 4.IB).
4.2.3 Real Time RT-PCR
In view of the low level of expression seen using RT-PCR and in-situ hybridisation,
real time RT-PCR was used to further delineate Aire mRNA. For these experiments,
adult CD1 thymus was used as a positive control, and was run on all plates as a
calibrator. Expression is determined as a fold change compared to this calibrator; n=3
for all tissues examined. The highest expression was seen in C57/BL6J thymus
(mean 4.3 fold higher than CD1 thymus; range 0.9-6.5) (Fig 4.2). All other tissues




Fig 4.1 RNA expression of Aire in murine tissues. A RT-
PCR of whole tissues from CD1 mice using primers specific for
Aire
B Expression of Aire mRNA is seen in the thymic medulla of
CD1 mice by in-situ hybridisation; i) antisense probe; ii) sense
probe (original magnification x200; scale bar represents 20pm)
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4.3 Expression of Aire mRNA in tissues of embryonic mice
Aire mRNA and protein expression have previously been described in the murine
thymus from E14.5 (23,5,7). However, there was no data on the distribution of Aire
elsewhere in the embryo, in particular in the haematologically/immunologically
important organs, liver and spleen. This was investigated at the mRNA and protein
level using in-situ hybridisation and immunohistochemistry, and the level of mRNA
expression was compared to that in the adult using real time RT-PCR
4.3.1 in-situ hybridisation
Aire expression was detected by ISH from El4.5 in the thymus of C57/B16J embryos
(Fig 4.3) this is in keeping with previous reports, Balb/C mice were used in one of
these reports (7), the mouse strain used is not specified in the others (23,5,7). No
other specific expression was seen by ISH.
4.3.2 Real Time RT-PCR
mRNA from C57/B16J spleen, thymus and liver at El6.5 was reverse transcribed to
use as the template for real time PCR. No amplification was detected even after 40
cycles from liver. There was however, amplification in both thymus and spleen (Fig
4.4A). In view of the lack of amplification in liver, other tissues, in which Aire
mRNA expression would be expected to be lower, were not analysed.
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4.3.3 mRNA expression in the adult compared to the embryo
In order to determine the relative expression of Aire mRNA between the adult and
the embryo, real time RT-PCR was performed on spleen and thymus, these tissues
were chosen as they express the highest levels ofAire.
In the spleen, expression in the embryo at El6.5 was 20 fold less than in the adult
(Fig 4.4B). A lower level of expression in the embryo compared to the adult was also




Fig 4.3 Aire mRNA expression at E14.5 demonstrated by in-
situ hybridisation. Aire mRNA expression demonstrated by in-situ
hybridisation in the thymic medulla A) antisense probe; B) sense probe












































Fig 4.4 Aire mRNA expression in embryonic mice
demonstrated by real time RT-PCR. A cDNA from whole tissues
at E16.5. Data is represented as a fold change in mRNA expression
compared to the calibrator sample which has a value of 1; B+C Data
from individual mice is represented by an individual data point, the
mean is shown by the bar. B cDNA from whole spleen from adult and
El6.5 mice; C cDNA from whole thymus from adult and El6.5 mice.
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4.4 Expression of Aire protein in tissues of adult mice
Immunohistochemistry was performed on tissues from C57/BL6J mice. Peptide
preabsorbed Aire antiserum, preimmune antisera and secondary antibody were used
as controls in all tissues examined, and no staining was seen (Fig 2.6).
Aire expression within the thymus (Fig 4.5A) was most marked within the thymic
medullary epithelial cells, with occasional medullary and cortical non-epithelial cells
also staining. In lymph nodes (Fig 4.5B), the light zone of the germinal centre of the
lymphoid follicles showed positive staining, whilst in the dark zone there was some
staining but the majority of cells were negative. Positive staining was also seen in the
T cell areas of the lymph node. This was also the case in spleen where the positive
staining was seen in the nuclei of cells in T cell areas of the white pulp (Fig 4.5C).
There was no staining in the red pulp.
In many other tissues including lung, kidney and fallopian tube, there was expression
within epithelial cells. This is illustrated in the large airways of the lung (Fig 4.5D)
where the only positive staining is in the epithelial cells. No staining was detected
within the small airways or alveoli.
Staining was observed in epithelial cells of the kidney (Fig 4.5E), within the tubules
and the glomerulus. Similarly, the columnar epithelium of the fallopian tubes also
stains positively.
No specific staining was seen in the epithelial cells of the small intestinal villi or in
the neuroendocrine cells of the gut, but strong staining was seen in the mucin spaces
of the goblet cells (Fig 4.5F). The significance of this is unclear, but loss of goblet
cells is a feature of autoimmune disease of the gut (110,111).
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Within the testis (Fig 4.5G), Aire staining was seen in the developing spermatocytes,
but not in the mature haploid cells, whilst in the ovary, staining was seen in the
follicular cells (Fig 4.5H). In the brain, staining was present in the neurones of the
hippocampus and cortex. All of this staining was absent in sections incubated with
pre-immune serum and was abolished by preabsorption of the Aire anti-serum with a
blocking peptide. No staining was seen in the heart (Fig 4.51), liver (Fig 4.5J) or any
zone of the adrenal gland (Fig 4.5K).
This pattern mimics that described above for real time RT-PCR, as tissues where a
greater population of cells stain have higher mRNA expression, e.g. thymus, spleen
and kidney. The only discrepancies between the real time PGR data and IHC are for
liver and heart, as mRNA expression is detectable in these tissues, albeit at low
levels, but no staining is seen in these tissues. This may reflect the fact that real time
RT-PCR is highly sensitive and is therefore able to detect a very low level of mRNA,
whilst protein expression is either absent or not detectable by IHC.
Immunohistochemistry was also performed on tissues from the outbred strain CD1,
the pattern of staining seen is consistent with that in the inbred strain C57/BL6J (data
not shown).
When compared to the study of Halonen et al (6), the obvious discrepancy is that
they report staining in the zona glomerulosa of the adrenal gland and in the liver in
hepatocytes and Kiippfer cells, but as can be seen in figures 4.5J+K, no positive
staining was seen here. In view of this, western blotting of liver and adrenal gland
was undertaken. This confirms the absence of Aire protein in these tissues in this
system (Fig 4.6). Ideally, the antibody used by Halonen et al should be used to
investigate the tissues examined here, as this differential staining most likely
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represents as difference in the 2 antibodies used. Unfortunately, the antibody used by
Halonen et al was not available.
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Fig. 4.5 Immunohistochemistry of murine adult tissues
demonstrating expression of Aire. A Thymus; B Lymph node; C
Spleen; D Lung; E Kidney; F Gut; G Testis; H Ovary; I Heart; J Liver;
K Adrenal Gland. A,C,D,E,F,G,H,I,J original magnification x200; B,K
original magnification xlOO; scale bar represents 20 pm
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Aire (~57kDa)
Fig 4.6 Western blot demonstrating lack of Aire expression in
liver and adrenal gland. Whole thymus is used as a positive control,
and Aire is detected at ~57kDa as expected. No expression is seen in liver
or adrenal gland.
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4.5 Expression of Aire protein in tissues of embryonic mice
mRNA expression was seen from E14.5, therefore, IHC was undertaken from E14.5.
Aire protein expression within the thymus was seen from E14.5 (Fig 4.7A) to term.
Unlike the adult, expression was seen at El4.5 in the liver (Fig 4.7C) and remained
at El 8.5 (Fig 4.7D), presumably reflecting that this is the main site of
haematopoiesis in the embryo.
Staining was also observed in the epithelial and interstitial cells of the developing
lung (Fig 4.7E+F) in the large airways, as demonstrated in the adult. Unlike the
adult, positive staining was detected in the epithelial cells of the gut at E14.5 (Fig
4.7G). This staining decreased but remained present towards term, and was
accompanied by the presence of staining in the mucin spaces of goblet cells, in the
same pattern as the adult (Fig 4.7H).
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Fig 4.7 Immunohistochemistry of murine
embryonic tissues at E14.5 and E18.5. A Thymus
E14.5; B Thymus El 8.5; C Liver E14.5; D Liver El 8.5;
E Lung E14.5; F Lung E18.5; G Gut E14.5; H Gut




These results reveal the presence of Aire protein in immunologically relevant murine
tissues and a restricted number of peripheral tissues. In the thymus, mRNA and
protein was detected primarily within the medulla as previously published for both
human and murine tissue (51,8,7,6). Thymic medullary epithelial cells have a role in
tolerance induction through clonal deletion (112), the induction of anergy (113) and
by supporting the development of regulatory T cells (114). As patients with APS1
have a breakdown in tolerance leading to autoimmune disease, the expression of Aire
in this particular tissue is not surprising. Negative selection of autoreactive T cells
within the thymus is an important mechanism in the prevention of autoimmune
disease. Therefore, the increased expression of Aire seen in models of negative
selection and the absence of Aire in the RelB-deficient mouse, in which there is a
defect in negative selection are further important clues to Aire's function, although
interpretation of the data in the RelB-deficient mouse is complicated by the fact that
it has defective thymic development (71,7). These data, in addition to the recently
described Aire knock-out mice, in which there is a defect in ectopic expression of
peripheral antigens in the thymus (13) and failure of deletion of organ specific T
cells within the thymus (75), show the importance of Aire in the induction of central
(thymic) tolerance.
In the lymph node, Aire expression has previously been reported in human and
mouse. However, the pattern of expression in lymph node and spleen seen here is
different to that reported by Halonen et al (6), who found no staining in B cell areas,
compared to the staining in both B and T cell areas demonstrated above. They also
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failed to detect Aire in the white pulp of the spleen (6), this is in contrast to the
specific staining in the T cell areas of the white pulp shown here (Figure 4.5C).
In addition to the immune system, immunostaining was seen in epithelial cells of the
lung, kidney, neurones within the cortex and hippocampus, in the ovary and testis
and in the goblet cells of the gut. This goblet cell staining raises concern regarding
the specificity of the antibody used here, as this pattern of staining is seen when non¬
specific staining is present, however, this staining was not seen in the absence of
anti-Aire antiserum and in slides stained with pre-immune serum. The expression of
the Aire protein in the lung, kidney and brain is more restricted in this study than in
the earlier ones (6,115).
These discrepancies may be explained by the use of different antibodies in the two
studies. The antibodies may recognise different epitopes, the peptide used by
Halonen et al. is slightly different to that used here, as it overlaps the sequence used
by 5 amino acids. Strain differences between the inbred C57/BL6J mice used in this
study and the outbred NMRI mice used by Halonen et al. (6) may also account for
variation in the pattern of staining. However, the pattern of protein expression in the
outbred strain CD1 was similar to that in C57/BL6J mice. A study on Balb/C mice
(7) revealed protein expression in the thymic medulla as demonstrated here, but not
in other tissues examined including testis, adrenal gland, lymph node, spleen and
liver.
In the embryo, in common with another report (23), Aire mRNA was detected in the
thymus by in-situ hybridisation from E14.5. Using the more sensitive technique of
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real time RT-PCR Aire mRNA was detected at low level in the spleen. Protein
expression was also seen from E14.5 and persisted through to El8.5. Expression was
also seen within the embryonic liver from E14.5 and towards term, consistent with
the liver's role in haematopoiesis. Expression of protein and mRNA has also been
reported in the human fetal liver (8).
In the embryo as in the adult. Aire expression is present in the epithelial cells of the
lung and developing renal tubules. Additionally, Aire expression is seen in the
epithelial cells of the gut at El4.5, as reported by Halonen et al. (6) in the adult. In
the embryo Aire is absent by El 8.5, and we observe the same pattern of expression
as in the adult, namely expression in the mucin spaces of the goblet cells only.
Positive staining for mRNA by in situ hybridisation was only seen in the thymus and
not in the other tissues studied. This may reflect either absent or very low levels of
expression in these tissues, below the limit of detection of this technique. These
findings complement those of others, as this is a common theme in previously
published work in mouse and human (23,8,73). In Balb/C mice Aire mRNA could be
detected outside the immune system but nested PCR was required due to low levels
of signal (7). The presence of low level expression is strongly suggested by real-time
PCR. The lack of staining seen in adrenal gland, suggests that the barely detectable
signal from real time PCR, may either be from a migrating cell type, as described by
Heino et al (7), due to the higher sensitivity of this technique, or Aire mRNA may be
shortlived in comparison to protein.
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In conclusion, the data described here show that Aire is expressed at the protein and
mRNA level in immunologically relevant tissues and in a restricted number of other
tissues in the adult. Novel data are presented on the expression of Aire protein in
extra-thymic tissues of the embryo. Of particular interest is the expression seen
within the immune privileged sites of testis and brain, especially in view of the high
proportion of male patients who develop testicular failure (4), and in the goblet cells
of the gut, which are lost in autoimmune disease at this site. The role of Aire in these





5 Cellular localisation and expression of Aire
5.1 Introduction
When transfected into epithelial or monocyte cell lines, human AIRE has been
observed to be localised predominantly in the nucleus in a speckled pattern (51,8,52).
This speckled pattern is similar to that seen with proteins that form nuclear bodies,
but AIRE does not co-localise with promyelotic leukaemia protein (PML) or SplOO
(51,52). It was therefore of interest to determine if AIRE co-localised with any other
nuclear proteins.
The previous subcellular localisation of Aire was determined in over-expressing cell
lines rather than primary cells, and in common with the tissue distribution of Aire,
there is a lack of a consensus about the cellular distribution of Aire. In their work on
the distribution of AIRE in human spleen, Heino et al described protein and mRNA
expression (8), and Bjorses et al found protein expression in lymphocytes in the red
pulp only (51).
In the mouse, Halonen et al found protein expression in the red pulp of the spleen in
lymphocytes and neutrophils (6), but in work by Heino et al, no protein expression
was detected in the murine spleen, and the mRNA expression seen there was
attributed to expression by splenic dendritic cells (7). As shown in the previous
chapter, a low level of mRNA expression was detected in the spleen by real time RT-
PCR, and protein expression was in the white pulp of the spleen, but not in the red
pulp.
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It should be emphasised that the staining in all of these previous papers is for Aire
alone. No double staining for cell surface markers has been performed, thus any
conclusions reached regarding the cell types expression Aire in the spleen are based
on morphology and geographical position.
Two groups have investigated AIRE protein expression in peripheral blood in
humans, with discordant findings. One group shows that on a smear of peripheral
blood leucocytes strong staining was seen in a Targe population' of lymphocytes,
neutrophilic granulocytes and monocytes. Paradoxically, in the same paper, once
these cells had been prepared as a cytospin, only approximately 5% of the cells
expressed AIRE protein (51). Kogawa et al, examined AIRE expression in MACS
purified populations of cells from peripheral blood. They found that AIRE mRNA
was detectable by RT-PCR in CD 14 positive cells but not in CD4 positive cells; the
same distribution was seen for protein expression, where 93% of CD 14+ cells stained
for AIRE whilst less than 3% of CD4+ cells were positive (72).
In mouse peripheral blood smears, lymphocytes, polymorphonuclear leucocytes and
monocytes stained positively for Aire, but there was no double staining of these cells
for cell surface markers (6).
Thus, there was a need to determine Aire expression in immune cell subsets, and to
investigate whether this would change on activation of the cells.
The aims of this chapter were
1. to investigate the relationship between Aire and other nuclear proteins
2. to characterise the expression of Aire in immune cell subsets
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3. to characterise the effect on Aire expression when these cells are activated
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5.2 Interaction with nuclear proteins
It is becoming increasingly evident that the location of a gene within a chromosome
territory of the nucleus plays a role in its ability to access the nuclear machinery
(116). This nuclear machinery encompasses many functions including transcription,
RNA splicing, protein modification and cell cycle control (117). The proteins
involved in these activities are contained in subcompartments of the nucleus or
nuclear bodies (118). These include PML bodies, coiled bodies, gems, splicing
speckles and nucleoli (117).
The pattern of AIRE expression in the nucleus has been noted to be reminiscent of
PML bodies, however, AIRE does not co-localise with PML or SplOO, which are
components of PML bodies (51,52).
Recently, a novel nuclear domain, termed paraspeckles has been identified (118).
Paraspeckles contain paraspeckle protein 1 (PSP1), paraspeckle protein 2 (PSP2) and
p54/nrb. p54/nrb has a role in transcriptional control, apoptosis, splicing, dsRNA
processing and co-transcriptional control through interacting with steroid hormone
nuclear receptors (119,120,121,122,123). PSP2 is a coactivator activator (124). The
function of PSP1 is unknown but it may be involved in transcriptional control (118).
The pattern of staining seen with Aire in the nucleus appeared similar to that of
PSP1, therefore the possibility that Aire and PSP1 co-localise was investigated.
Human adherent cells were used to investigate the co-localisation of AIRE and PSP1.
These cells were chosen as those in peripheral blood, which were likely to express
the highest levels of AIRE based on the evidence to date. It was necessary to use
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human cells, as the only anti-PSPl antibody available is an anti-human antibody that
does not cross react with mouse.
Both antibodies were raised in rabbit, therefore, the anti-Aire antibody was directly
FITC conjugated as described in section 2.13.1. Immunofluorescence was then
performed on the adherent PBMCs. The signal from the FITC-conjugated AIRE,
although detectable, was weak and was therefore amplified by using an anti-FITC
antibody followed by an Alexa Fluor 488 antibody (Molecular Probes). Binding of
the anti-PSPl antibody was detected with an anti-rabbit Alexa Fluor 594 and the
images captured using a confocal microscope (Section 2.13.8).
Both proteins were detected within the nucleus in a speckled pattern that co-localised
(Fig 5.1). No staining was observed in the absence of the primary antibodies, and
staining by the secondary antibodies was specific as demonstrated in figure 5.2. In
view of this co-localisation, immunoprecipitation was performed with either anti-
PSPl or anti-AIRE antibodies. The resulting protein was subjected to analysis by
western blotting and the membrane was probed with the opposite antibody. This
demonstrated an interaction between the two proteins (Fig 5.3).
Immunofluoresence was also performed using anti-AIRE antibody and anti-SC35
antibody, a splicing factor present in the nucleus as speckles. No co-localisation was
observed (Fig 5.4).
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Fig 5.1 Co-localisation of AIRE and PSP1 within the cell.
Human PBMCs were adhered for 1 hour in serum free media. The
adherent cells were stained for A AIRE (green) and B PSP1 (red), and
co-localisation is seen as yellow (C), the nucleus is stained with
ToPro3 (blue); images were captured using a confocal microscope. D
i) Pixel intensity along the line shown is depicted in ii) and confirms
that there is co-localisation of AIRE and PSP1.
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PSP1 PSP1 Aire Aire
primary secondary Primary secondary
A X V X
B ■/ S X
C X V S
Fig 5.2 Control slides for double immunofluorescence
with anti-AIRE and anti-PSP1 antibodies. The antibodies used
are shown in the table. AIRE (green), PSP1 (red) and the nucleus is








Fig 5.3 Immunoprecipitation of protein from human adherent
PBMC's shows an interaction between AIRE and PSP1. A+B
Immunoprecipitation with anti-AIRE antibody; A Membrane probed using
anti-PSPl antibody; B no primary control; C+D Immunoprecipitation with







Fig 5.4 AIRE and sc35 do not co-localise. A Human
adherent cells were stained with FITC labelled anti-Aire
antibody (Green) and anti-sc35 antibody (red). No co-
localisation was observed. B No primary control.
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5.3 Aire expression in lymphocyte subsets
Given the controversy regarding whether Aire is expressed in lymphocytes and
which, if any subsets it is seen in, the expression of Aire in immune cell subsets was
investigated by immunohistochemistry. Briefly, T and B cells were isolated by
mechanical disruption of the spleen, purified by MACS and stained using anti-Aire
antibody. FACS analysis to check cell purity was also performed.
5.3.1 Aire expression in splenic B cells
B cells were isolated from the spleens of C57B1/6J and BALB/c mice by positive
selection for CD19 (Miltenyi Biotech). Cell purities as assessed by FACS were 90%
and 93% respectively. The majority of these cells (>95%) express Aire protein, but
the level of staining seen was not as bright as for NK and T cells (Fig 5.5). To
confirm this observation, splenocytes from C57B16/J and BALB/c spleens were
double stained with the anti-Aire antibody and an anti-IgDb antibody (Section
2.13.8). Staining for Aire was observed in IgDb positive cells (Fig 5.8).
5.3.2 Aire expression in splenic T cells
CD3+ T cells were isolated from the spleens of C57B1/6J and BALB/c mice by
negative selection using a T cell isolation kit (Miltenyi Biotech). Cell purities as
assessed by FACS were 94% and 95% respectively. The majority of these cells
(>95%) express Aire protein (Fig 5.6).
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5.3.3 Aire expression in CD4+ and CD8+ T cells
In view of the expression in CD3+ lymphocytes, expression in CD4+ T cells was
investigated. CD4+ T cells were isolated from C57/B16J and BALB/c spleens by
negative selection using a CD4+ T cell isolation kit (Miltenyi Biotech). In 3 separate
experiments using pooled C57/B16J spleens the cell purity was 85-90%. These cells
express Aire protein (Fig 5.7B). CD4+ T cells from BALB/c spleen also express Aire
protein (Fig 5.7A). This staining was confirmed to be in CD4+ cells by double
staining with anti-Aire antibody and an anti CD4 antibody (Section 2.13.8) (Fig 5.8).
In a preliminary experiment to investigate whether AIRE is expressed in human
CD4+ T cells, these cells were purified from a buffy coat by depletion of other cell
subsets using a CD4+ T cell isolation kit (Miltenyi Biotech). In contrast to work
published by Kogawa et al (72) these cells do express AIRE protein (Fig 5.7C).
Expression of Aire in CD8+ splenocytes was investigated, by double staining with
anti-Aire antibody and an anti-CD8 antibody (Section 2.13.8), CD8+ cells also





Fig 5.5 Splenic B cells express Aire. Aire expression by IHC in
CD 19+ splenic cells isolated by MACS. A C57/B16J B BALB/c i)
Positive staining; ii) Negative control; iii) FACS analysis to show
purity of cells obtained by MACS purification. Isotype control
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Fig 5.6 Splenic T cells express Aire. Aire expression by IHC in
splenic T cells isolated by MACS. A C57/B16J B BALB/c i) Positive
staining; ii) Negative control; iii) FACS analysis to show purity of
cells obtained by MACS purification. Isotype control staining is




Fig 5.7 Aire is expressed in CD4+ T cells isolated from BALB/c and
C57BI6/J mouse spleen and human peripheral blood. Cells were stained
with anti-AIRE antibody (red); the nucleus was stained with ToPro3 (blue). A
BALB/c CD4+ T cells; B C57B16/J CD4+ T cells; C Human CD4+ T cells.
159
Fig 5.8 Aire protein is expressed in CD4+ and CD8+ T cells
and B cells isolated from C57BI6/J and BALB/c spleen.
Splenocytes are stained with anti-Aire antibody (red) and
antibodies against either CD4, CD8 or lgDb (green), the
nucleus is stained with ToPro3 (blue). A BALB/c splenocytes
stained for Aire and CD4; B C57B16/J splenocytes stained for Aire
and CD4; C BALB/c splenocytes stained for Aire and CD8; D
C57B16/J splenocytes stained for Aire and CD8; E BALB/c
splenocytes stained for Aire and IgDb: F C57B16/J splenocytes stained
for Aire and IgDb.
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5.4 Aire expression is increased in activated CD4+ T cells
Aire is known to have a role in central tolerance, however, the prevention of
autoimmune disease is also dependent on the peripheral control of any autoreactive T
cells, which do exit the thymus. The role of Aire in controlling a peripheral T cell
response is unknown, but restimulation in vitro with HEL, in the Aire deficient
mouse leads to increased proliferation compared to wild type (74), and in APS1
patients there was a trend to an increase in maximal proliferation (as described in
3.5.2). Therefore, the role of Aire in peripheral T cells was investigated.
CD4+ T cells were isolated from murine C57/B16J spleens, the spleens were
mechanically disrupted and the CD4+ cells magnetically isolated by negative
selection (section 2.14), cell purity was 85-90%. These cells were then activated
using plate bound anti-CD3 antibody at O.lpg/ml and soluble anti-CD28 antibody at
5 pg/ml for 24 or 48 hours (section 2.15.1), after which cell proliferation, assessed by
the incorporation of tritiated thymidine (section 2.16), and up-regulation of activation
markers, as demonstrated by FACS analysis, were used to determine activation
status. Aire mRNA and protein expression were determined. Each experiment used
pooled spleens, typically 4-6, and the data shown is from 7 individual experiments.
At both 24 and 48 hours the CD4+ T cells proliferated in the presence of anti-CD3
and anti-CD28 antibodies, indicating that the cells had been activated (Fig 5.9). The
activation markers, CD25 and CD69 were also up-regulated as shown by flow





















































Fig 5.9 Proliferation of C57/BI6J CD4+ T cells, as measured
by the uptake of tritiated thymidine, in response to
activation with anti-CD3 and anti-CD28 antibodies. A
Proliferation at 24 hours; B Proliferation at 48 hours. Data are






















Fig 5.10 CD25 and CD69 are up-reguiated upon activation
of C57BI6/J CD4+ T cells at 24 hours. A CD25 expression on
resting CD4+ T cells; B CD25 expression on activated CD4+ T cells;
C CD69 expression on resting CD4+ T cells; D CD69 expression on
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Fig 5.11 CD25 and CD59 are up-regulated upon activation
of C57BI6/J CD4+ T cells at 48 hours. A CD25 expression on
resting CD4+ T eells; B CD25 expression on activated CD4+ T cells;
C CD69 expression on resting CD4+ T cells: D CD69 expression on
activated CD4+ T cells. Data are representative of 4 experiments.
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5.4.1 Aire mRNA expression in activated CD4+ T cells
RNA was isolated from CD4+ T cells obtained as described above, reverse
transcribed and used as the template for real-time RT-PCR using specific primers
and probes for Aire (section 2.12.4). Five independent experiments were performed;
in experiments 4 and 5 Aire expression was up-regulated at 24 hours. Aire
expression remained up-regulated in experiment 4 at 48 hours and was also up-
regulated in experiments 2 and 3 (Fig 5.12).
5.4.2 Aire protein expression in activated CD4+ T cells
Immunohistochemistry was performed on CD4+ T cells, using an anti-Aire antibody,
the nucleus was delineated by staining with To-Pro3 and images were captured using
a confocal microscope (section 2.13.8). Aire protein expression was up-regulated on










































Fig 5.12 Real Time RT-PCR demonstrating Aire mRNA
expression in activated CD4+ T cells. CD4+ T cells were purified
from C57/B16J spleens and activated with anti-CD3 and anti-CD28
antibodies for A 24 or B 48 hours. The resting cells are used as the
calibrator for each experiment. Data is plotted as individual data points for
each experiment (n=5), the mean is represented by the bar.
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Fig 5.13 Activation of C57/BI6J CD4+ T cells up-regulates
Aire protein expression. Immunofluorescence of resting and anti-
CD3/anti-CD28 treated CD4+ cells. Aire (red) Nucleus (blue) A
Resting cells (original magnification x63); B Resting cells (original
magnification xl26); C Activated cells (original magnification x63);
D Activated cells (original magnification xl26); E Resting cells -
negative control (original magnification x63); F Activated cells -
negative control (original magnification x63). Data are representative
of 3 experiments.
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5.5 Aire mRNA and protein expression is also increased in
activated BALB/c CD4+ cells
These experiments were also performed using BALB/c mice (as described above and
section 2.15.1), however, for these experiments anti-CD28 antibodies were used at 1
pg/ml, as this concentration gave a similar increase in proliferation as 5pg/ml. In
addition to investigating protein expression at 24 and 48 hours, a 72 hour time point
was included in these experiments and cells were also stimulated with anti-CD3
antibodies alone as well as in combination with anti-CD28 antibodies.
Aire mRNA expression was increased upon activation with anti-CD3 antibody in 3
out of 4 experiments, and in 2 out of 3 experiments with anti-CD3 and anti-CD28
antibodies at 24 hours (Fig 5.14A). At 48 hours Aire mRNA expression was
increased in 2 out of 4 experiments when CD4+ T cells were activated with both
anti-CD3 and anti-CD28 antibodies (Fig 5.14B). No up-regulation in mRNA was
seen at 72 hours (Fig 5.14C).
Aire protein expression was up-regulated on activation by 24 hours in these
experiments and remained increased at 72 hours, no difference was observed in Aire
expression between cells activated with anti-CD3 alone compared to anti-CD3/28


















































































Fig 5.14 Aire expression is up-regulated in activated
BALB/c CD4+ T cells. Aire mRNA expression in resting, antiCD3
activated and anti-CD3/28 activated CD4+ T ceils at A 24 hours, B 48
hours and C 72 hours as determined by Real Time RT-PCR. The data
points represent individual experiments; data is calibrated to the
resting sample in each experiment; the mean is represented by the bar;
n=4.
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24 hours 48 hours 72 hours
Fig 5.15 Aire protein expression is up-regulated in BALB/c CD4+ T cells
activated with anti-CD3 antibody or anti-CD3 and anti-CD28 antibodies.
The scale bar represents 1 OpM. Data are representative of 3 experiments.
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5.6 Discussion
In summary, AIRE is expressed as speckles within the nucleus of human adherent
PBMCs where it co-localises with PSP1 but not with sc35. It is important to mention
that AIRE and PSP1 are not the same, this was determined by BLAST analysis of
protein and mRNA sequences of both Aire and PSP1. PSP1 is thought to be involved
in transcriptional regulation, in view of this it would be interesting to investigated
whether AIRE and PSP1 co-localise at all points in the cell cycle, as I have observed
that the pattern of Aire expression is different in cells which have mitotic spindles
present.
In addition to human adherent PBMCs, Aire mRNA and protein is also expressed in
murine T and B cells purified from spleen, and preliminary data suggests that in
contrast to work described by Kogawa et al (72) Aire protein is expressed in human
CD4+ T cells. Upon activation of murine CD4+ T cells, this Aire expression is up-
regulated at both the mRNA and protein level. This increase in expression occurs
upon activation with anti-CD3 antibody alone and with anti-CD3/28 antibodies,
however no obvious difference in protein expression was observed between cells
activated through the TCR alone compared to those activated through the TCR with
co-stimulation. TCR stimulation in the absence of co-stimulation was included as the
human AIRE promoter has been shown to contain a functional AP-1 binding site
(63). Analysis of the murine Aire promoter using TESS
(http://www.cbil.upenn.edu/tess/), which utilises TRANSFAC v4.0, also revealed an
AP-1 binding site. As co-stimulation is required for optimal activation of AP-1
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(125), it was possible that Aire may have been up-regulated more in the presence of
co-stimulation.
This data, in conjunction with that from the Aire deficient mouse, which has an
uncontrolled proliferative response upon rechallenge in-vitro with HEL (74), and the
trend to an increase in maximal proliferative response in patients with APS1 (Section
3.5.2 and Fig 3.12A) suggest that Aire may have a role in controlling the
proliferative response in the periphery. Thus, functional Aire may be required in
lymphocytes to terminate the immune response, and the autoimmune diseases seen in
APS1 and the Aire deficient mouse, are a consequence (at least in part) of a failure to
terminate/prevent a peripheral immune response. This hypothesis could be
investigated by assessing whether Aire protein expression remains up-regulated after
proliferation has started to decline. Alternatively, the generation of an Aire
conditional knock-out mouse, in which Aire is deficient in T cells only, would help
to delineate not only the role of Aire in the proliferative response, but also the role of
Aire in peripheral T cells in a broader sense.
The up-regulation in Aire as described above was seen in CD4+ T cells, but Aire is
also expressed in CD8+ and B cells. Further investigation of the role of Aire in these
cells would be informative, as although CD4+ T cells will play a role in the
autoimmune diseases seen in APS1, autoaggressive CD8+ T cells are recognised to





6 Interaction of Aire and the Notch signalling pathway
6.1 Introduction
In the previous chapter, it was demonstrated that Aire is present in peripheral CD4+
T cells, and is up-regulated upon TCR mediated activation of these cells. This led to
consideration of the possibility that, in addition to Aire's role in the induction of
central tolerance, it has a role in T cell effector function. The Notch signalling
pathway, a family of highly conserved developmental genes, has a role in
determining T cell lineage commitment and has been shown to influence T cell
effector function (88,91). Work from the laboratory has shown that this pathway is
up-regulated by activation through the T cell receptor (RA Benson PhD Thesis,
University of Edinburgh 2004) as described in chapter 5 for Aire. In view of this, the
possibility that Aire may interact with the Notch signalling pathway was
investigated.
6.1.1 The Notch signalling pathway
The Notch signalling pathway was first identified in Drosophila and plays a role in
cell fate in decisions in many organisms (128). There is a wealth of information in
the literature, thus in this review, I shall limit myself, where possible, to data from
mammals and concentrate on the role of Notch in the immune system.
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Fig 6.1 Notch signal transduction Binding of Notch by ligand induces
an extra-cellular cleavage event, followed by intra-membranous cleavage
mediated by y-secretase. This releases the intra-cellular domain of Notch
which translocates to the nucleus, binds to CBF-l and via recruitment of co-
activators activates transcription of hesl.See text for detailed description.
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Overview of Notch Signalling
There are four single pass transmembrane protein Notch receptors in mammals
(Notch 1-4). The extra-cellular portion contains epidermal growth factor (EGF)
repeats and three membrane proximal Linl2/Notch/Glp-l (LNG) repeats; the intra¬
cellular region contains nuclear localisation sequences, a RAM (RBP-Jk associated
molecule) 23 domain, the ankyrin repeats, a transcriptional activator domain (TAD)
and a PEST (proline-, glutamate-, serine-, threonine-rich) sequence (Fig 6.1) (129).
During synthesis, the Notch receptors are cleaved by a furin-like convertase (SI
cleavage), to give a 180kDa fragment consisting of the majority of the extra-cellular
domain and a 120kDa fragment which is the rest of the extra-cellular portion and the
intra-cellular domain. These are non-covalently associated as a heterodimeric form
which is expressed at the cell surface (130).
There are five Notch ligands, Delta-likel, Delta-like3, Delta-like4, Jaggedl and
Jagged2. Following binding of the ligand, through its DSL (Delta, Serrate, Lag2)
domain, to the extra-cellular domain of the Notch receptor, an extra-cellular cleavage
event mediated by FACE (TNF-a converting enzyme), a member of the ADAM
metalloprotease family, occurs (S2 cleavage) (131). The membrane tethered
intracellular portion that remains after this cleavage event then becomes a substrate
for a further cleavage event (S3 cleavage) leading to the release of the intra-cellular
domain of Notch (NICD) (132). This proteolytic cleavage event is mediated by the
gamma secretase complex. The gamma secretase complex consists of presenilin
(133), nicastrin (134), aph-1 and pen-2 (135), and although all components are
required for assembly of the gamma-secretase complex, the activity of the complex
co-purifies with presenilin (136).
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Following this gamma-secretase mediated cleavage event, NICD translocates to the
nucleus where it binds to CBF1 (C-promoter binding factor 1) via the RAM 23
domain and ankyrin repeats (129). This binding displaces histone deacetylase
(HDAC) and recruits histone acetylases and Mastermind which leads to activation of
transcription (137,138).
There are numerous target genes of Notch including a family of basic helix-loop-
helix (bHLH) proteins, the HES (Hairy-Enhancer of Split) proteins, that are
expressed in the immune system (139) and NF-kB, the expression of which is
increased by signalling through Notch (140). Thus up-regulation of the HES genes is
commonly used as marker of Notch signalling.
Notch signalling can affect cell fate either through lateral inhibition or inductive
signalling. In lateral inhibition, both Notch receptors and ligands are expressed on
the same adjacent cell type, and over time through fluctuations in levels of the
receptor and ligand, one cell will preferentially express the ligand and the other the
receptor. The ligand bearing cell will then adopt the primary cell fate, and the
receptor bearing cell, in which active Notch signalling is occurring, will inhibit
development of the primary cell fate. In contrast, inductive signalling requires there
to be two different cell types, one expressing ligand, and the other expressing
receptor. Signalling can then occur in the receptor bearing cell to alter its cell fate.
These cell fate decisions are further influenced by the specific receptor-ligand
combination present, as signalling through different combinations can lead to
different outcomes.
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Notch Signalling in the Immune System
Within the immune system Notch signalling is involved in cell fate decisions
involved in lineage commitment such as T/B cell differentiation and a(3/y8 TCR
usage. Active Notch signalling is required for T cell commitment, in the absence of
Notch there is a block in T cell development and a bias towards B cell development
(141), whilst overexpression of Notch leads to an increase in T cell development at
the expense of B cells (142). Thymic epithelial cells express Notch ligands of the
Delta-like and Jagged families (143), thus it is likely that signalling from these
ligands allows the precursor to adopt a T cell fate. The data regarding ap versus y8
commitment is less clear. However, from the evidence available it seems that Notch
signalling favours the development of aP rather than y§ T cells (143). The final cell
fate decision process in which Notch appears to be involved is CD4/CD8 lineage
commitment, where Notch signalling promotes the development of CD8+ T cells
over CD4+T cells (144).
Once activated through the recognition of a peptide/MHC complex on a mature DC
within the lymph node, the mature peripheral T cell may differentiate into a Thl, Th2
or T regulatory cell, a process that Notch may also be involved in. Signalling
mediated by Dll and N3 has been shown to generate a Thl phenotype characterised
by an increase in IFNy production and up-regulation of T-bet expression (91), and
signalling through Jagged 1 has been shown to generate a regulatory population of T
cells which were able to transfer tolerance (88,89).
Two recent studies have shown that Notch receptors are expressed on T cells and
their expression is up-regulated following T cell activation (145,146). Through the
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use of inhibitors of the gamma-secretase complex, this work also showed that in the
presence of decreased Notch signalling, T cell proliferation and secretion of IL2 and
IFNy were reduced (145,146), whilst overexpression of the intra-cellular domain of
Notch 1 increased proliferation and expression of CD25 (145). Therefore, it is
possible that Notch signalling acts in a co-stimulatory manner to enhance T cell
function.
The aims of this chapter were
1. to confirm that Notch signalling is up-regulated in activated CD4+ T cells
2. to investigate the effect of inhibiting Notch signalling on Aire expression in
activated CD4+ T cells
3. to determine the effect on Aire expression of delivering a direct Notch signal
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6.2 Notch signalling is up-regulated in activated CD4+ T cells
The Notch signalling pathway is described in detail above. Briefly, binding of the
membrane bound Notch receptor by a ligand (either Delta-like or Jagged) causes
cleavage by the y-secretase complex and release of the intra-cellular portion ofNotch
which then translocates to the nucleus where it is able to signal. This signalling is
then able to increase transcription ofNotch target genes, such as Hesl.
To determine whether Notch signalling was occurring upon T cell activation, RNA
was used in a Real Time RT-PCR reaction with primers and probe specific for hesl.
CD4+ T cells were isolated from C57BL/6J spleens by magnetic beads as described
in section 2.14, and activated with anti-CD3 antibody (0.1 pg/ml) and anti-CD28
antibody (1 pg/ml) for 48 hours. Hesl mRNA was not detected even after 40 cycles
by real-time RT-PCR in resting cells, but was detected in activated cells. In a further
5 experiments, with CD4+ T cells from pooled C57BL/6J spleens activated with anti-
CD3 antibody (0.1 pg/ml) and anti-CD28 antibody (5pg/ml) for 24 or 48 hours, hesl
mRNA expression was up-regulated in 2 out of 5 experiments at 24 hours and in the
other 3 experiments at 48 hours (Fig 6.2).
To determine that the effect seen was not mouse strain specific, 3 experiments using
CD4+ T cells from pooled BALB/c spleens were undertaken. In these experiments,
CD4+ T cells were activated with either with anti-CD3 antibody (0.1 pg/ml) alone or
anti-CD3 (0.1 pg/ml) and anti-CD28 (1 pg/ml) antibodies for 24, 48 or 72 hours.
In 2 out of 3 experiments, hesl mRNA was increased at 24 hours in CD4+ T cells
activated with anti-CD3 alone, with a mean fold change in mRNA expression of
2.8±1.9, and increased in CD4+ T cells activated with both anti-CD3 and anti-CD28
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antibodies in the 2 experiments for which data are available, mean increase 2.5±0.6.
At 48 hours, hesl mRNA expression was increased by anti-CD3 alone in 1 out of 3
experiments, increasing from 0.67±0.58 up to 1±0.44, and was increased in all 3
experiments when activated with anti-CD3 and anti-CD28 antibodies, with a mean
increase of 2.77+1.7. At 72 hours, a decrease in hesl mRNA expression was











































Fig 6.2 Aiesf expression is up-regulated in activated
C57BL/6J CD4+ T cells, hesl mRNA expression in resting and
anti-CD3/28 activated CD4+ T cells at A 24 hours and B 48 hours, as
determined by Real Time RT-PCR. The data points represent


























































Fig 6.3 hes1 expression is up-regulated in activated
BALB/c CD4+ T cells, hesl mRNA expression in resting, antiCD3
activated and anti-CD3/28 activated CD4+ T cells at A 24 hours, B 48
hours and C 72 hours as determined by Real Time RT-PCR. The data
points represent individual experiments; data is calibrated to the
resting sample in each experiment; the mean is represented by the bar;
n=3.
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6.3 Aire mRNA expression correlates with hes1 mRNA
expression
The data obtained showing up-regulation of hesl mRNA expression is very similar
to that seen for Aire mRNA expression in the same experiments in both C57BL/6J
and BALB/c mice (See Fig 5.12 and 5.14 for Aire mRNA expression). In view of
this the possibility of an interaction between Aire and Notch signalling was
investigated further.
6.4 Notch signalling is inhibited by y-secretase inhibitors
In order to determine whether the up-regulation of Aire seen upon activation is due
to the Notch signalling that is occurring in these cells, an inhibitor of Notch
signalling was used.
After binding of a ligand to a Notch receptor, an extracellular cleavage event occurs.
The remaining membrane tethered intracellular portion of the Notch receptor is then
able to be a substrate for the y-secretase complex. Further cleavage by the y-secretase
complex releases the intra-cellular portion, which translocates to the nucleus where it
effects CBF1-dependent signalling. Therefore, by inhibiting y-secretase activity,
Notch signalling can be prevented.
The y-secretase inhibitor, MW167 has been shown to inhibit the y-secretase
dependent processing of Notch that is required for nuclear translocation of NICD
(147,148,149,150), with an IC50 of 16pM (151,152). Like the Notch receptors,
presenilin, the active component of the gamma-secretase complex, is cleaved during
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synthesis, this endoproteolysis is required to generate a functional protein (153).
When used at low concentrations MW167 has presenilinase activity (152) i.e. it
prevents this endoproteolysis and leads to a decrease in the amount of functional
presenilin present.
MW167 or DMSO, as a vehicle control, was added to C57BL/6J CD4+ T cells that
were cultured in the presence or absence of anti-CD3 (0.1 pg/ml) and anti-CD28
(lpg/ml) antibodies. MW167 was used at 5pM, a dose that will primarily affect
presenilinase activity (152) and 20pM at which y-secretase activity should be
affected. Previous work in the laboratory had investigated the effect of MW167 on
hesl mRNA expression in resting, anti-CD3 antibody stimulated and anti-CD3/28
antibody stimulated BALB/c CD4+ T cells. This work demonstrated a minimal effect
on hesl in resting cells after 24 hours with lOpM or 20pM of MW167, but a
reduction in hesl was observed in resting cultures by 48 hours, which neared
biological relevance when 1 OpM was used and was almost undetectable when 20pM
of MW167 was used. In anti-CD3 antibody activated cells, 20pM of MW167 was
required to reduce hesl expression. In anti-CD3/28 antibody activated cells, a
decrease in expression was present with lOpM MW167, this decrease reached
biological significance when 20pM was used (RA Benson PhD Thesis, University of
Edinburgh 2004).
This was confirmed in C57BL/6J mice, in resting CD4+ T cells, hesl mRNA
expression was detected by real time RT-PCR in the absence of MW167, but was
undetectable when 5 or 20 pM of MW167 was added into the culture. In anti-
CD3/28 antibody activated CD4+ T cells, hesl mRNA expression was reduced by
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40% by addition of MW167 at 20 pM (Fig 6.4). It would have been preferable to use
a higher concentration of MW167, which would have decreased hesl expression
further in activated T cells, however this was not possible due to the cost of MW167.
In order to determine that any effects seen by using the y-secretase inhibitor MW167
were due to inhibiting Notch signalling and not through altering the activation status
of the cells, the effect, if any, of this inhibitor on T cell proliferation and up-
regulation of activation markers was assessed.
Proliferation of C57BL/6J CD4+ T cells was not affected by MW167 at 5,10 or
20pM at 48 hours (Fig 6.5). In a further 3 experiments using BALB/c CD4+ T cells,
proliferation was unaffected by MW167 at 20pM even after 72 hours of culture.
To determine the activation status of the CD4+ T cells, up-regulation of the
activation markers, CD25 and CD69 was assessed by FACS staining (Section 2.18).
No differences in the up-regulation of either marker was observed by the addition of
MW167 at 20pM at 24, 48 or 72 hours in resting, anti-CD3 antibody activated or
anti-CD3/28 antibody activated BALB/c CD4+ T cells. Representative data obtained
at 48 hours are shown in figures 6.6-6.8 (n=3). In C57BL/6J CD4+ T cells, no
difference in up-regulation of CD25 or CD69 was observed in the presence of
MW167 at 10pM (n=3).
Notch 1 has been documented to have anti-apoptotic effects in T cells (154), and thus
it is feasible that by inhibiting Notch with MW167, which will inhibit all Notch
signalling, not just that mediated by Notchl, apoptosis may be increased. In view of
this, the degree of apoptosis present was assessed by FACS staining for AnnexinV
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Fig 6.4 Notch signalling is inhibited by the y-secretase
inhibitor MW167. hesl mRNA expression in anti-CD3/28 activated
C57B16/J CD4+ T cells as determined by Real Time RT-PCR. The

























Fig 6.5 Proliferation of C57BI6/J CD4+ T cells is not affected
by the y-secretase inhibitor MW167. Proliferation of CD4+ T
cells as assessed by the uptake of tritiated thymidine 48 hours after
activation with 0.1 pg/ml anti-CD3 and lpg/ml anti-CD28 antibodies
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Fig 6.6 MW167 does not affect surface expression
of CD25 and CD69 on resting cells. FACS staining
of BALB/c resting CD4+ T cells i) + DMSO or ii) MW167
20mM, with A CD25FITC or B CD69PE antibodies; n=3.
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Fig 6.7 MW167 does not affect surface expression of
CD25 and CD69 on anti-CD3 antibody activated cells.
FACS staining of BALB/c CD4+ T cells i) + DMSO or ii)



























Fig 6.8 MW167 does not affect surface expression
of CD25 and CD69 on anti-CD3/28 antibody
activated cells. FACS staining of BALB/c CD4+ T cells
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Fig 6.9 inhibition of Notch signalling does not affect the
number of cells undergoing apoptosis. A Resting cells +
DMSO; B Resting cells + 20pM MW167; C Anti-CD3 antibody
activated cells + DMSO D Anti-CD3 antibody activated cells +
20pM MW167; E Anti-CD3/28 antibody activated cells + DMSO
F Anti-CD3/28 antibody activated cells + 20pM MW167; n=3.
Representative data at 48 hours in CD4+ T cells from BALB/c
mice is shown.
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6.5 Aire up-regulation is decreased by inhibiting Notch
signalling
Six experiments were undertaken, using CD4+ T cells magnetically isolated from 4-6
pooled C57BL/6J spleens by negative selection. Cells were activated with anti-CD3
antibody (O.lpg/ml) and anti-CD28 antibody (1 pg/ml) and cultured in the presence
or absence of 10pM MW167 for 48 hours. As described above, no differences in
proliferation, up-regulation of activation markers or apoptosis were observed by
addition of MW167. In the 4 experiments in which immunofluorescence was
performed, Aire protein was up-regulated upon activation as described in section
5.4.2, and this up-regulation was prevented by addition of MW167 (Fig 6.10).
As the level of Aire protein expression appears to be higher in BALB/c mice than
C57BL/6J (fig 5.8), a further 4 experiments using BALB/c mice were performed.
CD4+ T cells were magnetically isolated by negative selection, activated with anti-
CD3 antibody (O.lpg/ml) alone or anti-CD3 antibody and anti-CD28 antibody
(lpg/ml) and cultured in the presence or absence of MW167, at 20pM. In all of these
experiments, Aire protein expression was increased at all time points upon activation
with either anti-CD3 antibody alone or with both anti-CD3 and anti-CD28
antibodies. Surprisingly however, the up-regulation observed with anti-CD3 antibody
alone could not be inhibited by MW167, but that seen with anti-CD3 and anti-CD28
antibodies could (fig 6.11).
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Fig 6.10 Up-regulation of Aire in activated C57BL/6J CD4+ T
cells is abrogated by inhibition of Notch signalling. A
Resting cells + DMSO; B Resting cells + 10|jM MW167; C Anti-
CD3/CD28 Activated cells + DMSO; D Anti-CD3/CD28 Activated
cells + lOpM MW167. Representative data at 48 hours are shown.
n=4.
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Fig 6.11 Up-regulation of Aire in activated BALB/c CD4+ T
cells is abrogated by inhibition of Notch signalling in the
presence of co-stimulation. A Resting cells + DMSO; B Resting
cells + 20pM MW167; C Anti-CD3 Activated cells + DMSO; D Anti-
CD3 Activated cells + 20pM MW167; E Anti-CD3/CD28 Activated
cells + DMSO.; F Anti-CD3/CD28 Activated cells + 20pM MW167.
Representative data at 72 hours are shown. n=4.
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6.6 Aire expression is up-regulated by signalling through
Delta-likel
The above data are supportive of an interaction between Aire and Notch signalling,
but the cells in this system are TCR activated and therefore a multitude of complex
processes will be occurring simultaneously. In view of this, it was important to
investigate the effect on Aire expression when a direct Notch signal is delivered in
the absence of a TCR signal.
A mouse fibroblast cell line (L cell), which has been transfected with class II MHC
(I-Ab) (designated parental L cells) and the Notch ligand Delta-likel (Dll), a kind
gift from Prof M Dallman, was utilised for this purpose (155). Characterisation of the
Dll L cells was recently reported by Wong et al, and they have been shown to
express higher levels of Dll mRNA than parental L cells, to actively signal through
the Notch receptor in a reporter assay for Notch ligand activity and to up-regulate
expression of the target gene hesl in T cells co-cultured with Dll L cells compared
to parental L cells (155).
C57B16/J mice were used for these experiments to match the class II on the L cells.
CD4+ T cells were purified from pooled spleens by positive selection (Section 2.14)
and co-cultured with Mitomycin C treated L cells (section 2.15.2) for 24 hours. Aire
protein expression was determined by immunofluorescence and RNA was obtained
for real time RT-PCR to assess Aire and hesl mRNA expression. To verify that T
cell activation was not occurring, cell surface activation markers were analysed by
flow cytometry, cell proliferation was assessed by the incorporation of tritiated
thymidine and cell division was determined by CFSE staining (Section 2.17). The
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gamma-secretase inhibitor MW167 was also added to four out of six experiments to
inhibit the Notch signal delivered by the Dll L cells. Cell purity was assessed by
flow cytometry and was 89-97% in the experiments in which MW167 was added.
The cell purities for the remaining experiments were 63% and 83%, data from the
experiment with a cell purity of 63% are not included, as this level of contamination
was considered to be unacceptably high.
6.6.1 Signalling through Delta-likel up-regulates hes1 expression
To ensure that Notch signalling is activated by co-culture with Dll L cells, hesl
mRNA and protein expression were determined. As can be seen in Figure 6.12, in
this preliminary experiment, both mRNA and protein expression are up-regulated
after 24 hours of co-culture, in comparison to co-culture with the parental cells.
Having shown that Notch signalling is up-regulated in CD4+ T cells co-cultured with
Dll L cells, it was important to inhibit this Notch signal using the gamma-secretase
inhibitor MW167. Due to the fact that the Notch signal delivered by the Dll L cells
was likely to be greater than that seen upon T cell activation, MW167 was used at
20,50 and lOOpM (Fig 6.13), and 100pM was required to decrease hesl mRNA
expression in T cells co-cultured with either the parental L cells or Dll L cells back
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Parental L cell Delta-likel expressing L cell
Cell CD4+ T cells co-cultured with
Fig 6.12 Notch signalling is up-regulated in CD4+ T cells co-
cultured with Delta-likel expressing L cells. A hesl mRNA
expression as measured by Real Time RT-PCR in CD4+ T cells co-cultured
with either parental or Delta-likel expressing L cells; B Hesl protein
expression by immunofluorescence in CD4+ T cells co-cultured with either





























Fig 6.13 Hes1 mRNA expression is decreased by MW167 at
100pM. Hesl mRNA expression was determined by Real Time RT-PCR.
All values are relative to CD4+ T cells co-cultured with parental L cells in
the absence of MW167.
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6.6.2 CD4+ T cells are not activated by co-culture with Delta-likel
expressing L cells
Prior to co-culture with parental or Dll L cells, CD4+ T cells were CFSE stained
(Section 2.17). After 24 hours of culture, cells were stained with anti-CD4 PE
antibody (Section 2.18) and CFSE labelling of the CD4+ cells was analysed by flow
cytometry. The cells did not divide in this 24 hour period (n=3) (Fig 6.14).
Cell proliferation by the incorporation of tritiated thymidine was also assessed. No
difference in proliferation was observed by culture with Dll L cells compared to
parental L cells in the presence or absence of MW167 at 100 pM (n=3) (Fig 6.15).
Surface expression of the T cell activation markers, CD25 and CD69, was
determined by flow cytometry (section 2.18). No difference in expression of these 2
markers was seen on CD4+ T cells co-cultured with parental or Dll L cells, and no
difference was observed by the addition of MW167 at 100 pM (Fig 6.16 and 6.17).
As for activated CD4+ T cells, it was important to determine that the y-secretase
inhibitor was not causing increased apoptosis. Cells were stained with 7AAD and for
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Fig 6.14 CD4+ T cells co-cultured with L cells do not
divide. CFSE staining of CD4+ T cells co-cultured with A
Parental L cells; B Parental L cells and lOOpM MW167; C
Delta-like 1 expressing L cells; D Delta-like 1 expressing L cells






















0 100 0 100
MW167 (nM)
lAb L cells DM L cells
Type of L cell CD4+ T cells co-cultured with
Fig 6.15 CD4+ T cells co-cultured with L cells do not proliferate.
Incorporation of tritiated thymidine by CD4+ T cells co-cultured with
Parental L cells +/- lOOpM MW167 or Delta-like 1 expressing L cells +/-














Fig 6.16 CD25 on CD4+ T cells is not up-regulated by co-
culture with L cells. FACS analysis of CD4+ T cells, gated on a
lymphocyte gate, stained with anti-CD25 antibody, co-cultured with
A Parental L cells; B Parental L cells and 100pM MW167; C Delta¬
like 1 expressing L cells; D Delta-like 1 expressing L cells and lOOpM
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Fig 6.17 CD69 on CD4+ T cells is not up-regulated by co-
culture with L cells. FACS analysis of CD4+ T cells, gated on a
lymphocyte gate, stained with anti-CD69 antibody, co-cultured with
A Parental L cells; B Parental L cells and lOOpM MW167; C Delta¬
like 1 expressing L cells; D Delta-like 1 expressing L cells and 100|aM
MW167. Data are representative of 3 experiments.
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Fig 6.18 Co-culture of CD4+ T cells with Delta-like 1
expressing L cells has no effect on the degree of
apoptosis observed. AnnexinV/7AAD staining of CD4+ T
cells to determine the degree of apoptosis. A Co-culture with
parental L cells + DMSO; B Co-culture with Delta-like 1
expressing L cells + DMSO; C Co-culture with parental L cells +
lOOpM MW167; D Co-culture with Delta-like 1 expressing L
cells + lOOpM MW167. Representative data from 2 experiments.
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6.6.3 Aire expression is up-regulated by signalling through Delta-likel
In all 4 experiments in which immunofluorescence was undertaken, Aire protein
expression was increased in CD4+ T cells co-cultured with Dll L cells compared to
co-culture with parental L cells (Fig 6.19).
6.6.4 Inhibition of Notch signalling inhibits Aire up-regulation by Delta-
likel
The up-regulation of Aire protein expression observed following co-culture with Dll
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Fig 6.19 Aire expression is up-regulated in CD4+ T cells co-
cultured with Delta 1 expressing L cells. A Aire mRNA expression as
measured by Real Time RT-PCR in CD4+ T cells co-cultured with either
parental or Delta-like 1 expressing L cells; B Aire protein expression by
immunofluorescence in CD4+ T cells co-cultured with either (i) Parental or
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Fig 6.20 Aire expression is not up-regulated in the
presence of MW167. CD4+ T cells co-cultured with either Parental
or Delta-like 1 L cells in the presence or absence of MW167. A Real
time RT-PCR; B Immunofluoresence for Aire (red), the nucleus is
stained with ToPro3 (blue); i) CD4+ T cells co-cultured with parental
L cells - MW167; ii) CD4+ T cells co-cultured with Delta-likel L
cells - MW167; iii) CD4+ T cells co-cultured with parental L cells +
MW167; iv) CD4+ T cells co-cultured with Delta-likel L cells +
MW167. Data are representative of 3 individual experiments.
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6.7 Discussion
Following the observation that Aire is up-regulated under the same conditions as
Hesl, one of the target genes of Notch signalling, the possibility of an interaction
between Aire and Notch was investigated. Further evidence for Notch signalling
occurring under these conditions is provided in 2 recent publications (146,145). In
work by Palaga et al, Notch 1 protein expression was increased upon activation.
Furthermore, Hesl was also up-regulated upon activation as was the active intra¬
cellular portion of Notch 1, demonstrating that signalling through Notch is occurring
to give cleavage and release of the intra-cellular portion which is then signalling to
Hesl (146). This was also demonstrated by Adler et al, who show that mRNA
expression of all Notch receptors is increased after antigen specific stimulation and at
the protein level, the active intra-cellular portion of Notch 1 was detected within 12
hours of activation (145).
For the data presented in this chapter, the increase in Notch signalling seen on T cell
activation was inhibited by the y-secretase inhibitor, MW167, this prevented the up-
regulation in Aire protein seen in the presence of co-stimulation. However, the up-
regulation of Aire protein seen when activation occurs solely through the TCR is not
inhibited by MW167.
Although it is arguably more relevant to have protein data, as presented here, as it is
this that will effect a biological response, the relative mRNA expression would also
be interesting. However, deriving any meaningful results from the real time RT-PCR
data obtained was problematic. This was mainly because Aire is expressed at very
low levels, and as such was at the limit of detection by real-time RT-PCR. As the
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cycle threshold was occurring within the plateau phase of the reaction rather than the
logarithmic phase any differences in expression are much more difficult to detect. An
added problem was determining the optimal kinetics for the reaction, as this appeared
to be slightly different in each experiment. Thus, to accurately determine the true
change in mRNA expression in each experiment would have involved a large
number of time points and would have been impossible in terms of the size of the
experiment and the cost of reagents.
Given its effects on cell proliferation and survival, it was important to ensure that any
differences seen were due to Notch signalling itself and not due to any effects its
absence may have on the cell. This was demonstrated in the system used here, i.e.
inhibition of Notch signalling, by the absence of any differences in cell proliferation,
up-regulation of activation markers and measurement of apoptosis. However, in
work using an alternative y-secretase inhibitor, compound E, Adler et al, find that
inhibiting Notch signalling decreases T cell proliferation, IL-2 production and CD25
expression (145). A decrease in proliferation of T cells is also described by Palaga et
al, when the y-secretase inhibitor, IL-CHO is used to inhibit Notch signalling, in
addition, they find a decrease in IFN-y production and NF-kB activity when Notch
signalling is inhibited (146). In a preliminary experiment using one of these
alternative y-secretase inhibitors, Compound E, no difference in proliferation was
observed, but a diminution in the up-regulation of CD25 upon activation was
observed in the absence of notch signalling. The same pattern of Aire expression was
observed, i.e. in the presence of co-stimulation Aire up-regulation was prevented by
inhibiting Notch signalling, this did not occur in the absence of co-stimulation. Aire
protein expression was also increased by delivering a direct Notch signal in the
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absence of TCR signalling providing further evidence that it is the Notch signal, and
not the TCR signalling that is leading to up-regulation of Aire. Again this up-
regulation could be prevented by the y-secretase inhibitor MW167.
An important question to address is the specificity of the gamma secretase inhibitor,
at the time this work was commenced MW167 was one of only two gamma secretase
inhibitors available. MW167 was chosen as there was data in the literature showing a
90% reduction in signalling through Notch (156). However, the gamma secretase
complex also cleaves amyloid precursor protein (APP) (133). APP is expressed at
low levels in lymphocytes (157,158) and its surface expression is increased upon
activation (158). APP has been shown to affect lymphocytes as APP peptides are
able to stimulate lymphocyte proliferation in humans (159). Thus, there is a
possibility that the results shown in this chapter are due to APP being affected by
MW167 rather than Notch signalling. A preliminary experiment with a y-secretase
inhibitor XI that inhibits cleavage of APP but not Notch, completely inhibited
proliferation of CD4+ T cells to either anti-CD3 antibody alone or anti-CD3/28
antibodies. However, as described above, no difference was observed in proliferation
when MW167 was used. These data suggests that MW167 was not affecting APP in
the system used here, and also raises the question, whether the difference in
proliferation observed by Adler et al (145) and Palaga et al (146) is due to effects on





The hypothesis of this work was that lack of functional Aire affects peripheral T cell
function. This was addressed in the following ways.
In chapter 3, the UK population of APS1 patients was characterised with regard to
phenotype and genotype. The predominant genotype consisted of the presence a
mutation in exon 8 of the AIRE gene (964dell3), which has previously been
suggested to be the common UK mutation (1). These patients have a wide variety of
autoimmune diseases, with no apparent genotype-phenotype correlation. This disease
heterogeneity led to problems investigating peripheral T cell responses in APS1
patients and therefore no significant differences were seen. One way to have more
confidence in the limited data set presented here, would be to increase the number of
controls studied, as this would ensure that the 'normal range' against which the
patients are compared is as accurate as possible. The use of the Aire deficient mouse
may help to clarify this issue, as these mice are all on the same genetic background,
which would eliminate any bias in phenotype due to the genetic variability seen in
humans.
In keeping with other reports (51,8,6,7), the data in chapter 4 show the presence of
Aire mRNA and protein in the murine thymus, predominantly within the medulla. In
the lymph node and spleen, Aire expression was seen in B and T cell areas, in
contrast to the 'T cell area only' staining reported previously (6). This Aire staining
was confirmed to be expression in both T and B cells by staining of purified
lymphocyte populations (Chapter 5). This may suggest a role for Aire in the
peripheral immune response in addition to its recently characterised role in the
development of central tolerance.
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Expression of Aire in other tissues was more restricted than in the previously
reported study (6). It is difficult to resolve these differences, as all the antibodies
currently in use, are polyclonal sera raised in house by the individual groups, and at
present there are no commercially available antibodies. A GFP construct under the
control of the Aire promoter could be developed to clarify this issue.
To further investigate the possibility of a role for Aire in peripheral T cells, CD4+ T
cells were activated through the TCR in the presence and absence of co-stimulation
and an increase in Aire mRNA and protein expression was observed (Chapter 5).
This observation was then investigated further with regard to an interaction with the
Notch signalling pathway, as components of this pathway had been observed to be
up-regulated under the same conditions (146,145).
When Notch signalling was inhibited by the y-secretase inhibitor, MW167, the up-
regulation of Aire observed in the presence of co-stimulation was inhibited. In CD4+
T cells that received only a TCR signal, Aire expression was increased irrespective
of the presence of a Notch signal (Chapter 6). In addition, evidence for an increase in
Aire expression caused by a direct Notch signal is presented, this increase is also
abrogated by the use of MW167 (Chapter 6).
As co-stimulation appears to be required to inhibit Aire expression in the absence of
Notch signalling, the role of co-stimulation in the regulation of Aire expression is of
interest. One possibility would be to explore this further using alternative methods of
co-stimulation e.g. CD40-CD40L, ICOS-B7, however as it is CD28 that is a major
source of co-stimulation this approach may not succeed. A more successful approach
may be to substitute IL2 for the CD28 signal, however, this assumes that the effects
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mediated by CD28 are through it up-regulating other transcription factors and not
through IL2 production.
There have been many difficulties in investigating the role of Aire in peripheral T
cell function. As this is a rapidly evolving field with limited reagents the first
challenge was to characterise the distribution of Aire in the system used here. This
lack of commercially available reagents has also meant that the work has been
descriptive, as the resources required to address these issues in a mechanistic way are
not freely available.
It is disappointing that no differences were observed in the distribution of peripheral
cell subsets and the responses of T cells to a polyclonal stimulus and this work
clearly needs to be expanded both in terms of numbers and the methods used to
confirm that this lack of a difference is not an artefact of the methods used. An
alternative approach would be to characterise antigen specific responses, e.g. to
tetanus toxoid, as this may reveal more subtle differences in the T cell proliferative
response than can be seen with the use of a polyclonal stimulus such as anti-CD3/28
antibodies. Use of an animal model rather than patients with APS1 to investigate the
role of Aire in the periphery would enable the investigation of antigen specific
responses in more detail, as although looking at a recall response to common
immunogens eg tetanus toxoid would be preferable to a polyclonal response, the
numbers of cells involved would, relatively speaking be small. However, if this were
investigated in a TCR transgenic mouse crossed with the Aire knock-out mouse, the
chances of seeing any differences present would be greatly enhanced.
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The development of an all-encompassing hypothesis based on the results presented
here has been challenging. The systems investigated are complex, with numerous
interactions, at a variety of different levels, such that completely dissecting out the
pathways will be a difficult process.
The results in chapter 6, suggest that Aire up-regulation is mediated by Notch
signalling. Thus, when a T cell is activated, surface expression of Notch 1 is
increased (146) leading to increased Notch signalling, which is able to mediate Aire
up-regulation. However, the lack of inhibition of Aire expression seen when Notch
signalling is inhibited in an anti-CD3 activated T cell is not in keeping with this
(Chapter 6). One possible explanation of this observation, is that Notch is required to
prevent CD28 mediated down-regulation of Aire. Signalling through CD28 leads to
the activation of cJun (160) which is able to bind to the Aire promoter, but functional
assays of AP-1 binding to Aire, which appears to be solely mediated through Jun and
not Fos, reveal that AP-1 binding activates a luciferase reporter construct and that
this activation is decreased when the AP-1 binding site in the Aire promoter is
mutated (63). If Notch is required to prevent CD28 down-regulation of Aire, then
one possible mechanism would be that binding of the Aire promoter by Jun has an
inhibitory effect on Aire transcription, which is not suggested by the available data
on Aire and AP-1 binding, but AP-1 has been shown to have inhibitory effects on
mdr-1 gene expression (161).
However, Notch signalling also affects AP-1, as binding of NICD to CBF1 represses
AP-1 transactivation (162) and inhibiting Notch signalling leads to a defect in NF-kB
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activation (146). Therefore, there are many different pathways through which Notch
signalling may affect the T cell, all of which will undoubtedly interact.
This putative interaction between Aire and Notch signalling clearly needs further
investigation, this may either be mediated through one of the components of the
Notch signalling pathway directly, or alternatively through alterations in cytokine
secretion in the presence of Notch signalling. To take this aspect of the thesis further
forward, the experiments described here, should first be repeated using the
alternative methods of inhibiting the Notch signal that are now available. The data
presented here would suggest that Aire is up-regulated by Notch signalling. Notch
signalling is up-regulated in an activated T cell, therefore, is it Notch signalling
rather than T cell activation that is leading to Aire up-regulation in activated T cells.
The investigation of Aire expression in a Notch knock-out mouse would help to
delineate this, however, due to redundancy in the Notch signalling system, this is
likely to prove difficult. If it is the effects of Notch signalling on cytokine secretion
that bring about the effect on Aire expression, a different approach will need to be
taken. Inhibition of Notch signalling decreases IFN-y production (146), and data
presented as a poster in 2002 by Moratto et al, shows that there is an AIRE binding
site in the promoter region of IFN-y, therefore the inhibition of Aire seen on Notch
signalling may reflect a decrease in IFN-y. This could be investigated further by
blocking IFN-y activity with a specific antibody and assessing the impact on Aire
expression in activated cells.
What might be the function of this regulation of Aire expression in CD4+ T cells? In
the Aire deficient mouse, a 3-5 fold increase in proliferation was observed upon in-
vitro re-challenge with HEL (74). This, coupled with the observation in chapter 5
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that Aire expression is increased upon activation, led to the thought that Aire may be
required to terminate the proliferative response. This hypothesis needs further
investigation and the approaches described above, namely the use of antigen specific
responses, and in particular TCR transgenic mice crossed with the Aire knock-out
mouse, should go some way to determining this.
Final thoughts
This work has started to address the issue of whether Aire has a role in the peripheral
T cell. In view of the widespread autoimmune disease seen in the absence of Aire,
the role of Aire in peripheral tolerance would be of interest, as although Aire has
been shown to affect central tolerance, not all autoreactive T cells will be deleted
within the thymus, thus mechanisms are required in the periphery to control these
cells. One avenue to explore in this respect would be the expression of Aire in
regulatory T cells, both resting and upon activation, or perhaps it would be more
interesting to investigate the effect upon Aire expression in the cells suppressed by
the regulatory population. In addition to CD4+ T cells subsets, work described here
reveals the presence of Aire in CD8+ T cells and in B cells, and the investigation of
the role of Aire in these cells will be of interest.
The hope when starting this work was that, as the absence of Aire mediates the
development of a monogenic form of autoimmune disease, the study of this gene
would provide insights into the mechanisms of autoimmunity not just in this small
population of patients, but also in the more common complex autoimmune diseases.
Work published during the course of this work has demonstrated an important role
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for Aire in central tolerance (13,75), which despite the lack of a correlation between
heterozygosity for AIRE mutations and complex autoimmune diseases, may still
prove to be of relevance in non-APS 1 patients. However, it is unlikely that Aire only
acts to regulate the ectopic expression of tissue specific antigens, making the data
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Abstract
Autoimmune polyendocrine syndrome type 1 (APS1) is a rare autosomal recessive human
disorder caused by mutations in the autoimmune regulator gene (AIRE) and characterized
by multiple autoimmune diseases. As reports of the tissue expression pattern of the murine
Aire gene are discordant, a comprehensive survey of Aire expression was undertaken in
adult and embryonic tissues at the mRNA and protein levels using real-time RT-PCR, in situ
hybridization, and immunohistochemistry. In the adult, the highest Aire mRNA expression
was in the thymus. All the other tissues investigated expressed Aire mRNA at low levels, but
it was barely detectable in the adrenal gland. Aire protein expression was observed in the
thymus, spleen, and lymph nodes. A common pattern was observed in other tissues, with
staining in epithelial cells. An exception to this was the gut, where staining was seen in the
mucin spaces. In embryonic tissue, Aire mRNA and protein expression was detected from
E14.5 in the thymus. In the fetal liver, unlike the adult, staining was observed at E14.5 and
decreased towards term. Thus, Aire is expressed in immunologically relevant tissues and in
a restricted number of extra-immunological tissues in the adult. Furthermore, the presence
of Aire protein is reported in extra-thvmic tissues of the embryo. Copyright © 2004 John
Wiley & Sons, Ltd.
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Introduction
Autoimmune polyendocrine syndrome type 1 (APS1),
also known as autoimmune polyendocrinopathy can¬
didiasis and ectodermal dystrophy (APECED), is a
rare autosomal recessive disorder characterized by
multiple autoimmune diseases [1]. As one of two
monogenic forms of human autoimmunity [2], APS1
represents an important paradigm in the study of
autoimmune diseases. The autoimmune regulator gene
{AIRE), mutations in which cause APS1 [3], encodes
a number of highly conserved motifs (four LXXLL
motifs, two PHD fingers, and a SAND domain), sug¬
gesting that it functions as a transcription factor [4-7],
Recently, AIRE was shown to form homodimers and
homotetramers that can bind DNA [8J. Murine Aire
cDNA shares a high degree of homology with human
AIRE [9-11] and the homozygous Aire knock-out
mice manifest similar autoimmune features to those
in patients with APS1 [12,13].
The pattern of human AIRE mRNA expression was
first described in 1997 by two independent groups
[4,5], Northern analyses showed expression in the thy¬
mus, lymph node, and fetal liver. AIRE expression
was also reported in the spleen and tissues affected
in APS1, such as the adrenal cortex and pancreas by
one group [4], but not by another [5], These differ¬
ences have been attributed to false-positive hybridiza¬
tion due, perhaps, to non-specific binding by a GC-rich
probe [7], Human AIRE protein expression, as deter¬
mined by immunohistochemical staining, is also seen
in thymic medulla, lymph node, spleen, and fetal liver
[14,15], but expression was not observed in tissues
other than these [15].
Reports of the tissue distribution of murine Aire
mRNA are also discordant. Although Aire mRNA
could not be detected by northern blot analysis
[9,10,16], RT-PCR revealed the presence of Aire
transcripts in the heart, lung, testis [9,15,16], thy¬
mus [16-18], and lymph node [17,18]. However,
there are conflicting reports of Aire mRNA expres¬
sion in the spleen [9,16,18], kidney, brain [9,17], and
liver [16,17], Furthermore, a single report found Aire
mRNA in the ovary, adrenal gland, and thyroid [ 16].
Similarly, Aire protein has been found in adult
thymic medullary epithelial cells [12,17,18] and in the
thyroid, gut, pancreas, and brain [12,18], However,
Aire protein expression in the spleen, lymph node.
Copyright © 2004 John Wiley & Sons, Ltd.
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adrenal gland, lung, ovary, liver, kidney, and testis
is discordant between studies [12,17,18].
In the murine embryo, Aire expression can be seen
using RT-PCR, in situ hybridization, and immuno-
histochemistry from embryonic day 14.5 in thymic
medullary epithelial cells [9,10,18].
Thus, not only is there a discrepancy between the
reported expression of Aire at the protein and mRNA
levels, but there is also variability in expression as
determined by the same technique between studies.
Since the distribution of Aire is crucial to the under¬
standing of its role in organ-specific pathogenesis, we
carried out a comprehensive survey of Aire expres¬
sion in adult tissues at the mRNA and protein levels
using in situ hybridization and the more sensitive tech¬
nique of real-time RT-PCR and immunohistochemistry
to clarify this issue. We determined protein expression
in the whole embryo, as, to date, only Aire expres¬
sion in the embryonic thymus has been described and




CD1 and C57BL/6J mice (B&K, Hull, UK) were
housed in the University of Edinburgh Animal Facil¬
ities in accordance with local guidelines. Embryonic
tissue was taken at embryonic (E) days 14.5, 16.5, and
18.5 from time-mated pregnancies, where embryonic
day 0 (E0) was determined by detection of the vaginal
plug.
RNA extraction
RNA was obtained from whole tissue by homogeniza-
tion, followed by extraction using Trizol (Life Sci¬
ences, Paisley, UK), according to the manufacturer's
instructions. All samples for use in real-time RT-PCR
were DNAse-treated (Promega, Southampton, UK).
Real-time RT-PCR
A Taqman-based system and an ABI Prism 7700
sequence detector were used for real-time RT-PCR.
All reagents were obtained from Applied Biosys-
tems (Warrington, UK). Reverse transcription was per¬
formed using the Multiscribe RTIV1 kit and random hex-
amer primers, according to the manufacturer's instruc¬
tions.
Primers were designed using Primer Express for
murine Aire [F — 5'CCT GGA TTT CTG GAG GAT
TCT CT 3' (nucleotides 282-304); R — 5'CCG TCC
AGG ATG CTA TGC A3' (nucleotides 339-356);
probe — 5'6FamCGG CTG TAC CGC TCC AGA
TTG TAG TCC T Tamra3' (nucleotides 308-335)]
(sequence accession number NM_009646.1) and PCR
was performed using Taqman Universal PCR Master
Mix"' plus 18S as an internal calibrator for each
Copyright © 2004 John Wiley & Sons, Ltd.
sample. All samples were run in triplicate. cDNA from
whole thymus from an adult CD1 mouse was used as
a positive control for all runs; all mRNA levels were
determined in relation to this.
In situ hybridization (ISH)
Aire was amplified from mouse thymus by RT-PCR
(primers: F — AAG AAG CCA GAT GGC AAC
TT; R — CGA GGA TGA GTG TGC CGT GT)
(nucleotide numbers 550-569 and 948-967; acces¬
sion number NM_009646.1) and the 418 bp prod¬
uct was cloned into PGEMTeasy vector. The insert
was confirmed by sequencing and the orientation by
restriction digest. Sense (control) and anti-sense 35S-
labelled RNA probes were generated from this plas-
mid using an appropriate RNA polymerase. Tissue
was obtained from 6- to 8-week-old CD1 mice, and
C57BL/6J embryos. Frozen sections (10 pm) were cut
and mounted onto poly-l-lysine-coated slides. Sections
were fixed in 4% paraformaldehyde, washed in PBS,
and acetylated (0.25% acetic anhydride in 0.1 m tri-
ethanolamine, pH 8.0). After pre-hybridization in an
SSC humidified chamber, the sections were hybridized
at 50 °C overnight with 35S-labelled probe (1 x
107 cps/slide) in an SSC humidified chamber. Slides
were washed and then RNAse-treated for I h at
37 °C, followed by further washes and dehydration in
alcohol. Slides were dipped in Kodak NTB2 emul¬
sion (Kodak, Hemel Hempstead, UK) and developed
2 weeks later. Tissue was counterstained with haema-
toxylin and eosin and then coverslipped.
Antibody
A rabbit polyclonal anti-human Aire antibody (des¬
ignated 2328.1) was raised by giving six injections
of a peptide consisting of Aire amino acids 147-165
conjugated to BSA. The immunoglobulin (Ig) was
then protein A-purified from serum according to the
manufacturer's instructions (HiTrap protein A affinity
column, Amersham Pharmacia Biotech, Bucks, UK).
Immunohistochemistry (IHC)
All IHC was performed on a Biogenex Optimax
plus automated staining system (Biogenex, Berkshire,
UK). Tissue was taken from C57BL/6J and CD1
mice into 4% buffered formalin and then processed
into paraffin wax blocks. Three-micrometre sections
were cut and mounted on Vectabond-treated slides
(Vector Laboratories. Peterborough. UK). Slides were
dewaxed in xylene, followed by antigen retrieval using
Vector antigen retrieval solution (Vector Laboratories).
Slides were blocked with 2% hydrogen peroxide,
followed by normal goat serum. The Aire antibody
was pre-absorbed with 20% mouse serum and 20%
goat serum overnight at 4°C. Slides were incubated
with the primary antibody (0.675 ng of Ig per slide)
for 2 h at room temperature, washed, incubated with
J Pathol 2004; 202: 180-187.
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a goat biotinylated anti-rabbit secondary antibody
(DAKO, Ely, Cambridgeshire, UK), washed and then
Vector RTU ABC (Vector Laboratories) was applied
and positive signal was detected by the addition of
diaminobenzidine (DAB) (DAKO). The slides were
counterstained with haematoxylin and coverslipped.
Avidin/biotin blocking (Avidin/Biotin blocking kit,
Vector Laboratories) was used on all tissues.
Western blotting
Protein was extracted from adult thymus, liver, and
adrenal glands by homogenization in lysis buffer
[50 mM Hepes (pH 7.5), 1% Triton X-100, 50 mM
NaCl, 50 mM NaF, 10 mM sodium pyrophosphate, 1%
aprotinin, 1 mM PMSF, 0.5 m sodium orthovanadate;
all from Sigma Aldrich, UK], Fifteen micrograms of
protein was resolved on a 10% SDS-PAGE gel and
analysed using the specific Aire antibody.
Cell purification
T and B cells were magnetically sorted from adult
C57BL/6J murine spleens. T cells were isolated
using a Pan T cell isolation kit, and B cells
positively selected using CD 19 microbeads on an
AutoMACS machine (Miltenyi Biotech, Germany),
according to the manufacturer's instructions. Cell
purity was assessed using anti-CD3 antibody for
T cells and anti-CD 19 antibody for B cells; both
antibodies were labelled with PE (Pharmingen, UK)
and analysed on a FACSCalibur flow cytometer
(Becton Dickinson, UK).
Immunofluorescence
Cells were smeared onto superfrost slides, air-dried,
fixed in 90% dry acetone-10% methanol, blocked in
Dako diluent, incubated with Aire antibody, washed,
incubated with a goat anti-rabbit unconjugated anti¬
body, washed, and incubated with an Alexa Fluor 568
goat anti-rabbit antibody (Molecular Probes, Leiden,
The Netherlands). All incubations were at room tem¬
perature for 30 min. Slides were then incubated with
ToPro3 (Molecular Probes) to allow visualization of
the nucleus, prior to coverslipping. Images were cap¬
tured using a Leica TCS NT confocal system (Leica
Microsystems, GmbH Mannheim, Germany).
Results
Characterization of antibody
Western blotting of murine thymic protein with the
rabbit polyclonal anti-human Aire antiserum revealed
a band of the expected molecular weight of Aire
(58 kD). The amino acid sequence of the peptide used
for immunization is homologous between mouse and
human at 11 of 19 amino acids. Specificity in mouse
was confirmed by immunohistochemistry, in control
sections by pre-absorption with peptide in excess, and
incubation of additional control sections with protein
A-purified Ig from pre-immune serum (Figure 1).
Staining was within the nucleus in a punctate pattern,
consistent with the subcellular expression previously
reported [14].
Expression of Aire in tissues of adult mice as
determined by real-time RT-PCR, ISH, and IHC
Aire mRNA expression was determined by real-time
RT-PCR and is presented relative to expression in
adult CD1 mouse thymus. The same cDNA sample
was used on each real-time PCR plate to standardize
between runs. The highest expression was seen in
C57BL/6J thymus and was over four times higher
than that seen in CD1 thymus. All the other tissues
investigated expressed Aire mRNA at varying levels
which were less than in the positive control. Low
levels of mRNA relative to thymus were seen in the
spleen, testis, kidney, liver, brain, lung, ovary, heart,
and gut, with barely detectable expression in adrenal
gland (Figure 2).
The level of expression of Aire mRNA was con¬
firmed by in situ hybridization, where detectable Aire
mRNA expression was limited to the thymic medulla.
Immunohistochemistry was performed on tissues
from C57BL/6J mice. Aire expression within the thy¬
mus (Figure 3A) was most marked within the thymic
medullary epithelial cells, with occasional medullary
and cortical non-epithelial cells also staining. In lymph
nodes (Figure 3B), the light zone of the germinal cen¬
tre of the lymphoid follicles showed positive staining,
whilst in the dark zone there was some staining but the
majority of cells were negative. Positive staining was
seen in the T-cell areas of the lymph node. This was
Figure I. Immunohistochemistry of murine thymus (x200;
scale bar represents 20 pm). (A) Negative control; (B) incubated
with Aire antiserum; (C) incubated with pre-immune serum;
(D) incubated with Aire antiserum pre-absorbed with peptide
Copyright © 2004 John Wiley & Sons, Ltd. J Pathol 2004; 202: 180-187.
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Figure 2. Real-time PCR. mRNA from whole tissues was reverse-transcribed and used as the template for PCR with specific
primers and probes to Aire. All samples were normalized to a positive control, which is given a value of I
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Figure 3. Immunohistochemistry of murine adult tissues. (A) Thymus; (B) lymph node; (C) spleen; (D) lung; (E) kidney; (F) gut;
(G) testis; (H) liver; (I) ovary. (A, C-l) x200; (B) x 100; scale bar represents 20 pm
also the case in the spleen, where the positive stain¬
ing was seen in the nuclei of cells in T-cell areas of
the white pulp. There was no staining in the red pulp
(Figure 3C). No staining was seen with either peptide
pre-absorbed antiserum or pre-immune antisera. The
presence of Aire protein in the T and B cells of the
spleen was confirmed by staining purified cells. Posi¬
tive staining for Aire was seen in both T and B cells,
although the staining in B cells was less marked than
in T cells (Figure 4).
In many other tissues including the lung, kidney, and
Fallopian tube, there was expression within epithelial
cells. This is illustrated in the large airways of the lung
(Figure 3D), where the only positive staining is in the
epithelial cells. No staining was detected within the
small airways or alveoli.
Copyright © 2004 John Wiley & Sons, Ltd. J Pathol 2004; 202: 180-187.
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Figure 4. Aire protein expression in T and B cells. (A) T cells, (i) Positive staining for Aire in CD3-positive T cells; (ii) negative
control; (iii) flow cytometry to demonstrate the purity of the T cells using an anti-CD3 antibody (isotype control shown in red).
(B) B cells, (i) Positive staining for Aire in CD 19-positive B cells; (ii) negative control; (iii) flow cytometry to demonstrate the
purity of the B cells using an anti-CD 19 antibody(isotype control shown in red)
Staining was observed in epithelial cells of the kid¬
ney (Figure 3E), within the tubules and the glomeru¬
lus. Similarly, the columnar epithelium of the Fallop¬
ian tubes also stained positively.
No specific staining was seen in the epithelial cells
of the small intestinal villi or in the neuroendocrine
cells of the gut, but strong staining was seen in the
mucin spaces of the goblet cells (Figure 3F). The
significance of this is unclear, but loss of goblet
Copyright © 2004 John Wiley & Sons, Ltd.
cells is a feature of autoimmune disease of the gut
[19,20].
Within the testis (Figure 3G), Aire staining was seen
in the developing spermatocytes, but not in the mature
haploid cells, whilst in the ovary, staining was seen in
the follicular cells. In the brain, staining was present
in the neurones of the hippocampus and cortex. All of
this staining was absent in sections incubated with pre-
immune serum and was abolished by pre-absorption
J Pathol 2004; 202: 180-187.
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with a blocking peptide. No staining was seen in the
heart, liver (Figure 3H), or any zone of the adrenal
gland.
This pattern mimics that seen by real-time RT-PCR,
as tissues where a greater population of cells stain have
higher expression, eg thymus, spleen, and kidney. The
only discrepancies between the real-time RT-PCR data
and IHC are for the liver and heart. IHC was also
performed on tissues from the outbred strain CD 1: the
pattern of staining seen is consistent with that in the
inbred strain C57BL/6J (data not shown).
In view of the difference in tissue distribution in
this study compared with that of Halonen et al [17],
western blotting of the liver and adrenal gland was
undertaken. This confirms the absence of Aire protein
in these tissues.
Expression of Aire in murine embryonic tissues as
determined by ISH and IHC
Aire expression was detected by ISH from El4.5 in
the thymus as previously reported [9,18], No other
specific expression was seen by ISH. Additionally,
Aire expression in the embryo in relation to the
adult was studied using real-time RT-PCR. In the
spleen, expression in the embryo at El6.5 was 20-
fold less than in the adult (Figure 5D). A lower level
of expression in the embryo than in the adult was
also seen in the thymus (data not shown). IHC was
undertaken from El4.5; expression within the thymus
was seen from E14.5 to term (Figure 5A). Unlike the
adult, expression was seen at E14.5 in the liver and
decreased towards term, presumably reflecting that this
is the main site of haematopoiesis in the embryo.
Staining was also observed in the epithelial cells of
the developing lung (Figure 5B), in the large airways,
and in the epithelial cells of the developing renal
tubules, as demonstrated in the adult. Unlike the adult,
positive staining was detected in the epithelial cells of
the gut. This staining decreased towards term and was
accompanied by the presence of staining in the mucin
spaces of goblet cells, in the same pattern as the adult
(Figure 5C).
Discussion
Our results reveal the presence of Aire protein in
immunologically relevant tissues and a restricted num¬
ber of peripheral tissues. In the thymus, mRNA and
protein were detected primarily within the medulla, as
previously published for both human and murine tissue
[14,15,17,18]. Thymic medullary epithelial cells have
a role in tolerance induction through clonal deletion
[21], the induction of anergy [22], and by supporting
the development of regulatory T cells [23]. As patients
with APS1 have a breakdown in tolerance leading to
autoimmune disease, the expression of Aire in this
particular tissue is not surprising. Defects in the appro¬
priate negative selection of autoreactive T cells within
the thymus are an important mechanism in the aetiol¬
ogy of autoimmune disease. Therefore, the increased
expression of Aire seen in models of negative selec¬

















Figure 5. Immunohistochemistry (IHC) and real-time RT-PCR of murine embryonic tissues. (A) Thymus 18.5; (B) lung EI4.5;
(C) gut EI8.5 (xlOO). (D) mRNA from whole adult and embryonic (EI6.5) spleen was reverse-transcribed and used as the
template for PCR with specific primers and probes to Aire. All samples were normalized to the adult tissue, which is given a value
of I
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mouse, in which there is a defect in negative selec¬
tion, are important clues to Aire's function, although
interpretation of the data in the RelB-deficient mouse
is complicated by the fact that it has defective thymic
development [18,24], These data, in addition to the
recently described Aire knock-out mice, in which there
is a defect in ectopic expression of peripheral anti¬
gens in the thymus [13] and failure of deletion of
organ-specific T cells within the thymus [25], show the
importance of Aire in the induction of central (thymic)
tolerance.
In the lymph node, Aire expression has previously
been reported in human and mouse. However, in this
study, the pattern of expression in the lymph node and
spleen is different from that reported by Halonen et al
[17], who found no staining in B-cell areas, whilst we
found staining in both B- and T-cell areas. Halonen
et al [17] failed to detect Aire in the white pulp of
the spleen. In contrast, we showed specific staining in
the T-cell areas of the white pulp (Figure 3C). This
staining in the T- and B-cell areas was confirmed by
the presence of staining in T and B cells isolated from
the spleen (Figure 4).
In addition to the immune system, immunostaining
was seen in epithelial cells of the lung, kidney,
neurones within the cortex and hippocampus, in the
ovary and testis, and in the goblet cells of the gut.
Expression of the Aire protein in the lung, kidney,
and brain is more restricted in this study than in the
earlier ones [17,26],
These discrepancies may be explained by the use of
different antibodies in the two studies. The antibodies
may recognize different epitopes: the peptide used by
Halonen et al is slightly different from that used here,
as it overlaps the sequence that we used by five amino
acids. Strain differences between the inbred C57BL/6J
mice used in this study and the outbred NMRI mice
used by Halonen et al [17] may also account for
the variation in the pattern of staining. However, the
pattern of protein expression in the outbred strain
CD1 was similar to that in C57BL/6J mice. A study
on BALB/C mice [18] revealed protein expression in
the thymic medulla as demonstrated here, but not in
other tissues examined including the testis, adrenal
gland, lymph node, spleen, and liver. Therefore, in
the adult, we would agree that Aire is seen within
immunologically relevant tissues and in some non-
immunological tissues. However, protein expression
as detected by our antibody appears not to be as
widespread as that reported by Halonen et al [17],
The staining detected within T cells is of great
interest and clearly needs to be investigated further.
These data clearly show that Aire is expressed in
splenic T cells, as was suggested by the positive
staining seen by Halonen et al in the T-cell areas
of the spleen. Aire has been reported to be present
in some bone marrow lymphoblast stem cells [17].
However, its expression is less marked in thymocytes,
but is then detectable in the majority of splenic T cells:
this observation is in agreement with that of Ramsey
Copyright © 2004 John Wiley & Sons, Ltd.
et al [27]. As described above, it is established that
Aire has a role in central tolerance, by controlling
the expression of some tissue-specific antigens [13]
and through Aire-mediated central tolerance to high-
affinity T cells [25]. However, the presence of Aire in
peripheral T cells may suggest a role in mediating
peripheral tolerance. Ramsey et al found that Aire
knock-out mice have a greater proliferative response
to in vitro re-challenge with HEL than wild-type mice
[12], It is therefore possible that Aire has a role in
controlling the proliferative response in the periphery.
In the embryo, in common with another report,
we detected Aire mRNA in the thymus by in situ
hybridization from El4.5 [9] and using the more
sensitive technique of real-time RT-PCR, we detected
Aire mRNA at low level in the spleen. Protein
expression was also seen from El4.5 and persisted
through to El8.5. Expression was also seen within
the embryonic liver from E14.5 and towards term,
the expression of Aire was less marked, consistent
with a decline in the liver's role in haematopoiesis.
Expression of protein and mRNA has also been
reported in the human fetal liver [15].
In the embryo, as in the adult, Aire expression was
present in the epithelial cells of the lung and develop¬
ing renal tubules. Additionally, Aire expression was
seen in the epithelial cells of the gut at E14.5, as
reported by Halonen et al [17] in the adult. In the
embryo, Aire was absent by E18.5 and we observed
the same pattern of expression as in the adult, namely
expression in the mucin spaces of the goblet cells only.
Positive staining for mRNA by in situ hybridization
was seen only in the thymus and not in the other
tissues studied. This may reflect either absent or very
low levels of expression in these tissues, below the
limit of detection of this technique. These findings
complement those of others, as this is a common theme
in previously published work in the mouse and human
[9,15,16], In BALB/C mice, Aire mRNA could be
detected outside the immune system, but nested PCR
was required due to low levels of signal [18]. The
presence of low-level expression is strongly suggested
by real-time PCR. The lack of staining seen in the
adrenal gland suggests either that the barely detectable
signal from real-time PCR may be from a migrating
cell type, as described by Heino et al [18], due to the
higher sensitivity of this technique, or that Aire mRNA
may be short-lived in comparison to protein.
In conclusion, we have demonstrated that Aire
is expressed at the protein and mRNA levels in
immunologically relevant tissues and in a restricted
number of extra-immunological tissues in the adult.
For the first time, we have shown that Aire protein
can be detected in extra-thymic tissues of the embryo.
Of particular interest is the expression seen, firstly,
within the immune privileged sites of the testis and
brain, especially in view of the high proportion of male
patients who develop testicular failure [1]; secondly,
in the goblet cells of the gut, which are lost in
autoimmune disease at this site; and thirdly, in splenic
J Pathol 2004; 202: 180-187.
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T and B cells. The role of Aire in these tissues
remains to be elucidated, but these data raise questions
regarding its role in the regulation of tolerance in the
periphery, in addition to its role in the maintenance of
central tolerance [13,25,28].
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Rapid Onset Childhood Cataracts




James A. Deane, FRCOphth,
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Karen Adamson, MRCP, Simon Pearce, MRCP,
and Geoffrey Woodruff, FRCOphth
purpose: To report a case of bilateral cataracts in a child
that led to diagnosis of autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy.
design: Observational case report.
methods: A 12-year-old boy was being investigated for
weakness, lethargy, short stature, and blurred vision. He
developed bilateral, dense cataracts over a 2-week period.
He was found to be hypocalcemic and diagnosed with
hypoparathyroidism and autoimmune polyendocrinopa-
thy-candidiasis-ectodermal dystrophy.
results: Because of hypoparathyroidism, adrenocortical
failure, and insulin-dependent diabetes, it was 9 months
before the patient's metabolic imbalance was brought
under sufficient control to allow cataract surgery.
conclusion: Autoimmune polyendocrinopathy-candidi-
asis-ectodermal dystrophy should be considered with
diagnoses of hypocalcemic cataract. (Am J Ophthalmol
2003;136:951-952. © 2003 by Elsevier Inc. All rights
reserved.)
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as
autoimmune polyendocrinopathy syndrome type 1, is a
rare autosomal recessive disease characterized by a variable
combination of (A) failure of the parathyroid glands,
adrenal cortex, gonads, pancreatic beta cells, gastric pari¬
etal cells, thyroid gland, and hepatitis; (B) chronic muco¬
cutaneous candidiasis; (C) dystrophy of dental enamel and
nails; alopecia; vitiligo; and keratopathy.1
A 12-year-old boy was seen in the ophthalmology
department of the Leicester Royal Infirmary with a 6-week
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history of intermittent double vision. He was found to
have an intermittent right esotropia. A general deteriora¬
tion in his health was noted, with symptoms of weakness
and lethargy and problems with speech and writing. His
height was below the third percentile. He was admitted to
the pediatric department for further investigation. He later
complained of blurred vision; on review, he had developed
bilateral cortical lens opacities, that had not been present
2 weeks earlier (Figure 1). His visual acuity had deterio¬
rated from 20/40 (OD) and 20/20 (OS) to 20/200 in each
eye.
Serum calcium was 0.68 mmol/1 (normal, 2.10-2.60),
with a phosphate level of 3.22 mmol/1 (normal, 1.20-
2.30). The parathyroid hormone level was below detect¬
able limits at <0.1 pmol/1. Control of the mineral and
electrolyte balance proved to be difficult to achieve and
was complicated by the development of adrenocortical
failure. A clinical diagnosis of APECED was made.
Nine months after the appearance of the cataracts,
when the patient's general medical condition was suffi¬
ciently stable, bilateral phacoemulsification with intraoc¬
ular lens placement was carried out without complication.
Preoperative visual acuity had deteriorated to 3/180 in
each eye; postoperative visual acuity was 20/20 part in
each eye. The patient also developed a large-angle (48
prism diopter, near and distance) right convergent squint,
which was corrected following the cataract surgery. Sys¬
temic features of APECED seen in this case included
intestinal malabsorption without enterocyte antibodies,
alopecia, skin and nail changes, insulin-dependent diabe¬
tes mellitus, and delayed puberty.
Autoimmune polyendocrinopathy-candidiasis-ectoder-
mal dystrophy is caused by mutations in the autoimmune
regulator gene (AIRE).2 Analysis of this gene demon¬
strated that the patient was a compound heterozygote for
the most common UK mutation, 964dell3, which is
thought to give rise to a truncated nonfunctional protein,
and a second, as yet unidentified mutation.
Other ocular associations with this disease include
bilateral chronic keratitis, which may be a presenting
feature. The outcome following keratoplasty in these
patients is poor, with rejection occurring in all four
transplants of one series.3-4 Iridocyclitis, retinal detach¬
ment, and optic nerve atrophy may occur in rare cases.4-5
Rapidly progressive cataracts were the key feature
leading to the diagnosis of hypoparathyroidism and
APECED in this child. It is not known whether the
emergence of the convergent squint was related to the
disease. Ophthalmologists and pediatricians should con¬
sider APECED when making a diagnosis of cataract in a
patient with hypocalcaemia. Because some manifestations
may not appear until the fifth decade, all patients need
lifelong follow-up to detect new components of the dis¬
ease.1
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FIGURE 1. One of the bilateral, dense anterior and posterior cortical lens opacities, that appeared and progressed rapidly over a
2-week period.
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PURPOSE: To report a case of exudative retinal detach¬
ment due to small noncalcified retinal astrocytic hamar¬
toma and review pertinent literature.
DESIGN: Case report and review of literature.
METHODS: Clinical examination, fluorescein angiography,
optical coherence tomography, and laser treatment were
performed.
RESULTS: Exudative macular detachment caused by a
small noncalcified retinal astrocytic hamartoma con¬
firmed by optical coherence tomography regressed com¬
pletely after laser therapy. Visual acuity improved only
slightly because lamellar macular thinning developed
after subretinal fluid and macular exudates resolved.
CONCLUSIONS: Small noncalcified, parafoveal retinal as¬
trocytic hamartomas may cause macular retinal detach¬
ment. Optical coherence tomography may aid in the
diagnosis of the tumor. Argon laser photocoagulation
may induce tumor regression and resolution of exudative
detachment. Final visual acuity may be limited in some
cases. (Am J Ophthalmol 2003;136:952-954. © 2003
by Elsevier Inc. All rights reserved.)
Four types of retinal astrocytic hamartomasare described. Large atypical retinal astrocytic hamar¬
tomas are usually not associated with tuberous sclerosis or
neurofibromatosis especially when single and peripapil¬
lary.1 Most develop before age 20; few adult cases are
reported. Complications include exudative retinal detach¬
ment, vitreous hemorrhage, infarction, neovascular glau¬
coma, and blindness.1-2 Three typical forms, small
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